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ABSTRACT 
Introduction: Our findings and those of others show that the adult myocardium, including 
human, harbours a population of resident (endogenous) cardiac stem cells (eCSCs). They 
express the stem cell factor receptor c-kit, are distributed throughout the myocardium, are 
clonogenic, self-renewing and multi-potent, in that they differentiate into the 3 main cardiac 
lineages; cardiomyocytes, smooth muscle and endothelial cells in vitro and in vivo. The 
objective of this study is to determine whether c-kitpos eCSCs isolated from the different 
cardiac chambers have a distinct transcriptional profile depending on the chamber of origin. 
Methods: Pieces of myocardium have been obtained from all the 4 chambers of the adult 
human heart. All patients were fully consented before undergone open heart surgery. They 
were suffered of various cardiac pathologies such as ischemic heart disease, aortic, mitral and 
tricuspid valve insufficiency or stenosis, and various aortic pathologies. Ethical approval for 
these procedures has been given by NREC (08/H1306/91).c-kitpos eCSCs were isolated by 
enzymatic digestion and purified by Magnetic Activated Cell Sorting (MACS) from samples 
taken from the right and left atria (RA, LA), right and left ventricle (RV, LV) of the adult 
human heart. mRNA was isolated using Qiagen® mRNA kit, and reverse transcribed using 
first strand cDNA synthesis with random hexamers. qRT-PCR was performed using SYBR 
Green on a MyIQ thermocycler Bio-Rad® of specific genes representative of the primary and 
secondary heart field, and the developmental program of their chamber of origin.  
Results: c-kitpos eCSCs isolated from 15 human samples (5LA, 1RV, 4LV, 5RA) were 
processed. c-kitpos eCSCs are distributed throughout the human myocardium and in all 4 
chambers of the heart. Transmitted light microscopic observations of c-kitpos eCSCs revealed 
that the c-kitpos cells from the human biopsies were generally small and rounded, consistent 
with a stable c-kitpos eCSCs phenotype, regardless of the chamber of origin. The eCSCs c-
kitpos cells could be cultured under hypoxic conditions between 7 and 12 days to attain full 
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confluency. Expression of transcripts for c-kit, Foxh1, Hand1, Hand2, Pitx2, Tbx5, Tbx20, 
Hrt1, Hrt2, Fgf8, Fgf10, and Isl1 were found at differential levels in c-kitpos CSCs isolated 
from the four cardiac chambers. 
Conclusion: This study is the first to show that c-kitpos eCSCs derived from human adult 
cardiac samples, do not appear to have a ‘chamber-specific’ transcript footprint, and are 
therefore potentially interchangeable between cardiac chambers, raising the potential of their 
therapeutic application.  
 
Key words: human c-kitpos cardiac stem cells, left atria, right atria, left ventricle, right 
ventricle, transcriptional profile, primary heart field, secondary heart field. 
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1. INTRODUCTION 
1.1 Impact of Cardiovascular Disease. 
1.1.1 Cardiovascular disease and mortality. 
In the 21st century when most illnesses potentially can be cured, cardiovascular disease still 
remains one of the most serious pathologies that kill thousands of people worldwide. Each 
year cardiovascular disease causes over 4 million deaths in Europe, approximately 47% of all 
deaths and is equally prevalent in males and females. Overall cardiovascular disease is 
estimated to cost the EU economy ~ €196 billion per year (1). Of this total cost around 54% 
is due to patient formal health care costs, 24% due to productivity losses and 22% due to the 
informal care of people with cardiovascular disease (2). 
In the UK as in Europe, cardiovascular disease is the most prevalent pathology with chronic 
heart failure the most common cause of death and commonly associated with significant poor 
prognosis: 30–40% of patients diagnosed with chronic heart failure die within a year, but 
thereafter the mortality rate is 10% per year (3,4). Recent statistics in the UK identified 
approximately 900,000 people suffer from heart failure and every year 25,000 new cases 
recorded (5). Many of these patients have suffered from one or more myocardial infarctions 
in the past that have triggered myocardial damage and failure over time. Cardiac pathologies 
that could gradually damage the myocardium and progress to chronic heart failure include: 
hypertension, valve disease and cardiomyopathy.   
There are a number of risk factors that can trigger coronary artery disease and consequently 
ischemic, chronic heart failure: family history, smoking, increased alcohol consumption, 
diabetes, obesity and high cholesterol together with loss of physical activity and adoption of a 
sedentary lifestyle (6). All of these factors can result in damage of the coronary vasculature, 
placing the cardiac muscle in danger of a myocardial infarction with progressive and gradual 
cardiac failure. 
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Both the incidence and prevalence of chronic heart failure increase with age, with the average 
age at first diagnosis being 76 years in 2006 (7). The prevalence of chronic heart failure is 
expected to rise in the future as a result of an ageing population, improved survival of people 
with ischaemic heart disease and more effective treatments for heart failure (8). There is also 
evidence of a trend for improved prognosis, with 6-month mortality rate decreased from 26% 
in 1995 to 14% in 2005 (9). More than £500 million is spent annually on the treatment of 
chronic heart failure, which is ~ 1.4% of the annual health care budget (10). The overall rate 
of chronic heart failure hospitalisation per 10,000 people did not change significantly from 
2000 to 2010 (35.5 compared with 32.8), but the trends were different between those under 
and over age 65 showing that chronic heart failure is increasingly prevalent in younger 
individuals (11).  
1.1.2 Mechanisms of cardiomyocyte failure. 
Improved medical and surgical management in the past 30 years has produced a decline in 
the death rate due to cardiovascular disease. However, damage to the heart often leads to 
negative cardiac remodelling (12). Left ventricular remodelling can progress to biventricular 
heart failure and accelerated ventricular remodelling is a probable contributor to the increased 
mortality observed after myocardial infarction in hypertensive patients.  
A number of studies have shown that the failing human myocardium undergo significant 
changes that can lead to a steady and progressing loss of its contractile function. This can be 
seen in a molecular level and as well in a neuro-hormonal regulation level. There is in fact a 
decreased expression of ɑ-myosin heavy chain gene with increased expression of β-myosin 
heavy chain (13, 14, 15).Simultaneously there is progressive loss of myofilaments in 
cardiomyocytes, alterations in cytoskeletal proteins, alterations in excitation contraction 
coupling and desensitization of β-adrenergic signalling (16). Some of these changes it could 
be presumed that they are mechanisms of adaptation and could  be  beneficial in terms of 
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protecting cardiomyocytes against the potential deleterious consequences of excessive neuro-
hormonal activation, however when these changes are seen in a molecular and then functional 
level they could lead to a defect in cardiomyocyte contractile function, as well as decreased 
and loss of responsiveness to normal adrenergic control mechanisms, both of which are 
characteristics of failing human myocardium.  
Thus, the contractile dysfunction that develops within cardiomyocytes during the process of 
LV remodelling is likely to involve a number of genes, including those that regulate calcium 
handling, sarcomere turnover, ɑ-adrenergic signalling and the cytoskeleton, all of which may 
interact in an exceedingly complex manner within the cardiac myocytes to produce 
contractile dysfunction (17). The cellular basis of this cardiac deterioration is a decrease in 
the number of viable cardiomyocytes, secondary to either acute ischemic injury or chronic 
cell apoptosis/necrosis, which is not balanced by the adaptive hypertrophy of the remaining 
cardiomyocytes. To overcome the myocardial damage medical and surgical therapies have 
been implemented to reduce the loss of the healthy cardiomyocytes and improve cardiac 
function and patient symptoms with better quality of life and better outcomes; unfortunately 
the success on curing chronic heart failure is still debatable.  
1.1.3. Current treatment of cardiovascular disease. 
The use of triple medical therapy (ace-inhibitors, diuretics and β-blockers) in patients with 
chronic heart failure has improved the outcomes and delayed the progression of the disease. 
However, due to other multiple comorbidities, e.g. diabetes, obesity, hypertension despite 
maximal medical therapy and recently cardiac resynchronization therapy or CRT (18), the 
failing heart also affects other vital organs, including the kidneys and liver. More than 800 
medical clinical trials have been implemented, to determine the best medical treatment to 
cure and improve the quality of life of patients who are suffering with heart failure 
(www.clinical trials.gov). Surgical therapy cannot offer a better advantage to medical therapy 
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and in most of patient cases the long term solution is assist devices as a destination therapy or 
as a bridge to transplantation (19, 20). However the lack of donors and the long-term side 
effects of the anti-rejection medications together with the enormous cost of the assist devices, 
questions the future validity of this mode of intervention. Furthermore, current therapy cannot 
reverse the harmful remodelling and loss of myocytes that accompany injury. In light of the 
limited efficacy and poor side effect profile of current treatment options, alternative long-
term therapeutic strategies are needed which focus more on the cardiac repair, regeneration 
and remodelling processes. In theory if therapies could be developed to reverse or repair the 
myocardial damage, they could ameliorate an enormous public health burden, with an 
immediate effect on the quality of life and productivity of these patients.  
Over the last 20 years stem cell biologists and cardiovascular basic researchers have made 
interesting observations regarding revolutionary cell based therapies and their potential as 
viable treatment options for various cardiovascular conditions, including: acute myocardial 
infarction and chronic heart failure (21, 22). A number of clinical studies have been 
implemented to deliver stem cells, including: cells from the bone marrow, skeletal muscle 
myoblasts, adipose tissue-derived cells and more recently the use of endogenous resident 
cardiac stem cells (eCSCs), to repair the damaged myocardium. All have shown potential for 
myocardial repair and regeneration in patients with ischemic heart disease and chronic heart 
failure (23, 24). 
1.2. Cell-based therapy for the treatment of cardiovascular disease. 
Cell-based therapy is a relatively new approach to treat myocardial damage and is aimed at 
replacing diseased and lost myocardium with new healthy myocytes and vasculature. There 
are a number of ways that cell transplantation therapy could repair/regenerate damaged 
myocardial tissue and improve cardiac function, such as firstly direct trans-differentiation of 
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transplanted cells to new myocytes and vasculature (25), secondarily as paracrine effects of 
the transplanted cells on cardiomyocytes and vascular cells in recipient tissue (26), and 
thirdly as direct effects of growth factors on the eCSC population within the recipient tissue 
stimulating their differentiation into new cardiac cells (27). A number of different stem-
progenitor cells have been studied in the last decade as a potential source of new 
cardiomyocytes to ameliorate the injured myocardium, compensate for the loss of ventricular 
mass and contractility and eventually restore cardiac function (28). These include embryonic 
stem cells (ESCs), induced pluripotent stem cells (iPS cells), skeletal myoblasts, bone 
marrow derived cells (BMDCs) including mesenchymal stem cells (MSCs), endothelial 
progenitor stem cells (EPCs) and haematopoietic stem cells (HSCs), and recently endogenous 
cardiac stem-progenitor cells (eCSCs). Moreover, as opposed to cell transplantation, a new 
concept involves the activation of the resident eCSCs by growth factors (27, 29) and could be 
the future of regeneration of the damaged myocardium (30). 
1.2.1. Embryonic stem cells. 
Embryonic Stem Cells (ESCs) are derived from the inner mass of the blastocyst (31) and they 
can grow in vitro and be propagated indefinitely in their undifferentiated state while retaining 
a normal karyotype (32). They can maintain their property of multi-lineage commitment and 
therefore can differentiate into all cell types present in an organism (33, 34). Embryonic stem 
cells from a variety of animal species including human, which can differentiate into 
cardiomyocytes and other cell types present in the heart (35, 36). In vitro experiments have 
mostly relied on spontaneous differentiation of ESCs in embryonic bodies (EBs) to form 
contracting outgrowths containing cardiomyocytes (37).  A range of different cardiomyocyte 
cell types can be obtained from ESCs including: nodal-like, atrial-like and ventricular-like 
cells (38). Indeed, implantation of beating EBs has been shown to reverse atrio-ventricular 
block in pigs (39). Techniques are evolving to enrich and purify these different populations of 
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cardiomyocytes, together with the impact of certain cytokines or growth factors on cardiac 
lineage differentiation of ESCs (40). Animal studies in vivo suggest that ESC-derived 
committed cardiac cells have the capacity to significantly improve myocardial function and 
structure after MI, through generation of new cardiomyocytes in the infarcted area (41). 
Furthermore, ESC-derived endothelial cells positively stimulate angiogenesis and improve 
myocardial contractility in mice following Myocardial Infarction (42), which may facilitate 
recovery or reduce damage.  
Although the research on ESCs is growing, there are some serious concerns regarding their 
safety, use and their effectiveness in the treatment of human diseases, with significant ethical 
and regulatory concerns regarding their retrieval and usage for the purpose of treating 
patients with chronic diseases. In addition to these issues, there is a risk of developing 
malignancies, intra and extra-cardiac teratomas or other tumours associated with the 
transplantation of ESCs (43, 44).  Furthermore, following allogeneic application, ESCs will 
trigger an immune response in the recipient (45, 46), requiring the need for 
immunosuppression, if the grafted cells are to be sustained. Finally, it remains elusive as to 
whether human ESCs efficiently engraft and electromechanically integrate into ischemic 
myocardium (47). As a result of these limitations, potentially hindering the transition of ESC 
based therapy into clinical translation (48), viable alternatives must be sought. Indeed, 
scientists have invested extensive research into identifying and characterising alternative 
models. The discovery of Takahashi and Yamanaka of the  induced pluripotent stem cells 
(iPs) cells and the use of them has opened new opportunities for stem cell research (49), 
offering a number of alternative routes for furthering clinical applications without 
compromising health or individual beliefs (50).  
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1.2.2. Induced pluripotent stem cells (iPS cells). 
The discovery by Takahashi & Yamanaka (49) that embryonic and mature mouse fibroblasts 
can be induced to become pluripotent stem cells by retroviral transduction of four 
transcription factors Oct3/4, Sox2, c-Myc and KLF-4 has revolutionised regenerative 
biology. The creation of iPS cells from human fibroblasts (51) heightened clinical appeal and 
led to rapid implementation of these cells as a source of cardiomyocytes (52, 53). These 
clonogenic, multipotent and autologous iPS cells can be created from a skin biopsy, hair 
follicle cells or blood (54). They allow potential disease modelling, drug discovery, as well as 
the generation of potentially large numbers of autologous cardiomyocytes, which could be 
used for transplantation, without the risk of rejection. Like the ESCs, iPS cells can form 
various types of cardiomyocytes including atrial, ventricular and nodal cells (55). However, 
as with ESCs, these cells also   retain the potential to form tumours, posing a future risk, 
which needs to be verified and surmounted. Alternative methods to create iPS cells avoiding 
the use of viral vectors (i.e. small molecules) are currently being investigated to overcome 
this important limitation (56). Another important issue concerning the cardiogenesis of iPS 
cells is their long term stability and integration into the myocardium, as many iPS-derived 
cells are incompletely differentiated and remain immature in phenotype compared to their 
mature cell counterparts (57, 58).  Therefore, while promising, these cells are currently not 
viable for clinical use in the regeneration of damaged myocardium. 
1.2.3. Skeletal myoblasts.  
Skeletal myoblasts have been used and transplanted into the infarcted heart with the goal to 
restore cardiac function (59). Two large, well conducted, phase I-II studies carried out by the 
MAGIC TRIAL showed that there was attenuation in LV remodelling, which was cell 
number dependant. Unfortunately this was not accompanied by functional cardiac 
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improvements (60). The failure of the myoblasts to improve cardiac function in humans has 
been attributed to their inability to differentiate into cardiac myocytes and the in situ 
development of dysfunctional electrical coupling with the resident cardiomyocytes (61). One 
of the major concerns raised by the early-phase studies of myoblast transplantation was that it 
could increase the risk of ventricular arrhythmias, a complication attributed to the slowing of 
conduction velocity by the electrically isolated islet-like clusters of myoblasts and the 
subsequent occurrence of re-entry cardiac arrhythmias. Results from the double blinded 
randomised MAGIC trial showed that at the 6-month study point, the proportions of patients 
who had experienced arrhythmias did not differ significantly between the pooled treatment 
groups and the placebo group. Nevertheless, the actual number of arrhythmias was two times 
greater in each of the myoblast treated groups than in the placebo group, which clearly calls 
attention to a pro-arrhythmic risk of myoblast implantation. Indeed, there are on-going 
concerns, despite these early results that skeletal myoblast therapy can precipitate cardiac 
arrhythmias making them a non-viable cell model (62). 
1.2.4. Bone marrow derived cells (BMDCs). 
On the search for potential transplantable stem cells, experimental and clinical studies have 
tested BMDCs for a range of therapeutic strategies including their mobilization to sites of 
cardiac injury. Three meta-analyses (23,24,63) evaluating data from approximately 18 trials 
concluded that BMDC-based therapies contribute to modest improvements in cardiac 
function by reducing infarct size of injury, preserving LV dimensions and increasing ejection 
fraction by 2-3% within 6-12 months from transplantation. The mechanisms underlying the 
modest benefits of BMDC therapy remain poorly understood, although enhanced 
angiogenesis and reduction in myocyte apoptosis through a paracrine effect of the BMDCs, 
(64), differentiation of BMDCs into cardiac cells (65) and activation of the resident eCSCs 
(66) have all been suggested and are discussed further below. 
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1.2.5 Haematopoietic stem cells (HSCs). 
A hematopoietic stem cell is a cell isolated from the blood or bone marrow (BM) that can 
renew itself, can differentiate to a variety of lineage specific specialized cells, can mobilize 
out of the bone marrow into circulating blood and can undergo programmed cell death. 
Identifying and characterizing properties of HSCs began with studies in mice, which laid the 
groundwork for human studies (67). Approximately 1/10,000 to 1/15,000 bone marrow cells 
are believed to be stem cells. In the blood stream the proportion falls to 1 in 100,000 blood 
cells. New treatments using HSCs include graft-versus-tumour therapy for currently incurable 
cancers, autologous transplants for autoimmune diseases and gene therapy and tissue repair 
for a host of other problems. The adequate production of blood cells is maintained by a set of 
immature HSCs located in the bone marrow after birth. HSC are able to reconstitute the 
hematopoietic system in disease-related bone marrow failure and bone marrow aplasia (68).  
In current treatments, HSCs can be mobilized from the bone marrow into the peripheral blood 
using hematopoietic cytokines, allowing a convenient harvest of these cells for clinical 
transplantation. Moreover, reports suggest that HSCs of mesenchymal lineage can trans-
differentiate into a wide variety of phenotypes, including cardiomyocytes (25). Studies by 
Orlic (69) reported extensive regeneration in sites of myocardial infarcts, after direct injection 
of an adult BM population enriched for hematopoietic stem cells (Lin-, c-kit+) into the 
ischemic heart. In another study by the same group, similar effects were observed following 
the mobilization of BM cells into the peripheral circulation by growth factors (70). These 
promising results have prompted several clinical trials (71, 72, 73, 74). However, the 
underlying concept is currently being challenged by studies in which several populations of 
HSCs (c-kit-enriched, Lin- c-kit+, Lin- c-kit+ Sca-1+, and Lin- Thy1.1low c-kit+ Sca-1+ BM 
cells of either a-MHC–nLAC or h-Act–EGFP transgenic donor mice) did not readily acquire 
a cardiac   phenotype but rather adopted traditional hematopoietic fates after direct 
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transplantation into ischemic myocardium (75, 76). Despite the techniques and cells 
available, the knowledge that researchers have in terms of stem cell transplantation is still in 
development, therefore we await further studies in order to realise the full promise of HSC-
based therapy, in for example, myocardial regeneration.  
1.2.6 Endothelial progenitor cells (EPCs). 
EPCs can be isolated from peripheral blood as circulating BMDCs, based on the expression 
of HSC surface markers such as CD34, CD133 and vascular endothelial growth factor 
receptor  2 (VEGF-R2). The main mechanism of action of these cells is the formation of 
endothelial cells and new vessels in the infarcted myocardium (77) and their ability to 
produce endothelium has been demonstrated in vitro (78). In rats With Acute Myocardial 
Infarction, intravenous injection of EPCs can stimulate development of collateral vessels 
from pre-existing vessels as well as de novo capillary formation (79).  
This group reported that there was decreased apoptosis of myocytes in the borderline zone, 
reduced fibrosis and scar formation resulting in prevention of LV remodelling and 
improvement in myocardial function. In patients with old MI and chronic, total coronary 
artery occlusion, intracoronary infusion of EPCs after recanalization of the occluded artery 
improved myocardial perfusion, reduced infarct area and ameliorated myocardial function 
(80). However, a clinical trial using EPCs was terminated prematurely due to potential 
adverse reaction of increased restenosis (81). There is little evidence for their in vivo trans-
differentiation into new cardiac myocytes (65). 
1.2.7 Mesenchymal stem cells (MSCs). 
Mesenchymal stem cells (MSCs) can be isolated from a variety of tissues such as adipose, 
umbilical cord, umbilical cord blood and bone marrow. They lack hematopoietic lineage 
markers such as CD14, CD34 and CD45 but they express stromal surface markers such as 
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Stro1, CD105, CD90 and CD71. They have reduced expression of levels of MHC class I and 
lack class MHC II so they potentially provide prototypic immune-privileged cell based 
therapies and have been tested in phase I double blind randomised clinical trials as an 
allogeneic graft (82). These cells have a multifactorial action on cardiac regeneration with 
trans-differentiation capacities (83), and effects mediated by secreted factors and cytokines 
that evoke a therapeutic response (84). Recent studies reported that the MSCs can facilitate 
cardiac regeneration through mechanisms that involve differentiation and paracrine 
stimulation of innate repair pathways (85). Particularly MSCs seem to have a unique capacity 
to activate the endogenous c-kitpos cardiac stem cells (eCSCs) and establish the correct 
cardiopoietic milieu that can support or even guide the eCSCs to regenerate a myocardial scar 
(86, 87) demonstrated that allogeneic MSCs transplanted into the infarcted mouse 
myocardium survived for up to 6 months. At 2 weeks, the transplanted MSCs did not express 
cardiomyocyte specific markers (e.g. α-actinin, myosin heavy chain, phospholamban, and 
tropomyosin), when assessed by confocal microscopy. However at 3 and 6 months expression 
of α-actinin, myosin heavy chain, phospholamban, and tropomyosin were evident. MSCs 
improved global LV function at 4 weeks, at a time when the transplanted MSCs did not 
express a full complement of cardiomyocyte markers and ultimately differentiation was 
incomplete, with myofibril organization being immature. In addition, all of hearts at 6 months 
contained MSCs that expressed von Willebrand factor, which indicates a role for MSCs in 
angiogenesis. Although by 6 months post transplantation, the transplanted MSCs did express 
markers of adult mature cardiomyocytes, the improvement in LV function was no longer 
present; suggesting that the improvement in LV function at 4 weeks was due to a paracrine 
effect of these cells rather than their differentiation into new cardiomyocytes. Furthermore, 
not all the studies provide evidence of myocardial regeneration following MSC 
transplantation (87, 88) again suggesting further research is required. 
12 
 
The MSCs are promising cells for myocardial regeneration; the degree to which they 
differentiate does not explain in full their cardiac reparative properties (83). The most likely 
mechanism is that they stimulate regeneration of cells already present in the myocardium that 
are in a quiescent state, triggering mobilization of the eCSCs to repair the myocardial 
damage. This synergistic effect may enhance the potential of the endogenous cardiac stem 
cells in the process of regeneration, which could consolidate a link between MSC/eCSCs and 
the myocardial regeneration process (89, 90). 
1.2.8 Endogenous cardiac stem-progenitor cells (eCSCs). 
The discovery of populations of resident endogenous cardiac stem-progenitor cells including 
those in the adult human heart (Table 1.1) has revealed great potential in the field of 
myocardial regeneration and future clinical application for the treatment of the cardiac failure 
(91). In the last decade, cardiac stem cell research has made significant steps and challenged 
the dogma of the adult heart as a post-mitotic organ. Cells in the post-natal murine heart with 
a phenotype of ‘stem-like’ cells were first reported in 2002. These cells expressed the ATP 
binding cassette transporter Abcg2, extruded Hoechst dye (92), represented 1% of total 
cardiac cells and differentiated into cardiac myocytes in vitro. Subsequently two groups 
Anversa & Nadal-Ginard (93) reported endogenous c-kit positive (c-kitpos) cardiac stem cells 
(eCSCs) resident in the adult mammalian heart. More recently, endogenous cardiac stem-
progenitor cells have been shown to play a significant role in cardiac cell homeostasis and 
myocardial response to injury (94) and are viewed as integral in myocardial regeneration, 
representing probably the best candidate stem cells for long term reconstitution of the 
damaged myocardium either by direct cell transplantation or by stimulation of their 
regenerative capacities to produce new myocytes and vessels in situ by growth factors (95).  
The existence of cardiac-derived stem-progenitor cells has been confirmed by several 
independent groups (95, 96, 97, 98, 99,100,101) and although a variety of markers have been 
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proposed to identify eCSCs in different species, it still remains to be determined whether 
these markers identify different populations of eCSCs or, more likely, different 
developmental and/or physiological stages of the same cell type (see Table 1.1) (102). The 
different cardiac stem-progenitor cells identified to date are described in detail in the next 
paragraph. 
1.3. Tissue specific endogenous cardiac stem-progenitor cells. 
 
1.3.1. c-kit positive (c-kitpos) CD45 negative (CD45neg) eCSCs. 
One population of resident cardiac stem-progenitor cells can be identified through expression 
of the stem cell factor receptor, c-kit (c-kitpos), in addition to Sca-1 and MDR-1 (ABCG2). 
They are negative for markers of the blood cell lineage, CD31, CD34 and CD45. They have 
capacities of self-renewal, clonogenicity and multipotency, with significant myocardial 
regenerative capacity in vivo (97). They are capable of generating the 3 major cell types of 
the myocardium; cardiomyocytes, smooth muscle and endothelial vascular cells (see Figure 
1.2). When BrdU or EGFP tagged c-kitpos eCSCs were injected into the border zone of an 
experimentally produced infarction, a band of regenerating myocardium composed of tagged 
cells were observed in the infarcted zone. The labeled cells were either small cardiomyocytes 
expressing sarcomeric proteins or vascular cells forming new vascular structures (97).  
Since their discovery in the rodent heart, these endogenous c-kitpos eCSCs have been 
identified and characterized in other species, such as the dog (103), pig (27),sheep(104) and 
human (89,95,100,105). In the human, the density of eCSCs corresponds to 1 c-kitpos eCSC 
per ~1000 cardiomyocytes or ~50,000 eCSCs per gram of tissue (106). The c-kitpos eCSCs 
are the only cardiac progenitor cells proven to fulfil the requirements to be bona fide stem 
cells, being clonogenic, self-renewing and multipotent with significant cardiac regenerative 
potential in vivo. Not all these characteristics have been proven for all the other cardiac cell 
types described in Table 1.1 as shown below.  
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Table 1.1 Cardiac stem-progenitor cells and their characteristics identified in the mammalian 
heart. 
 
 
AUTHORS 
 
PHENOTYPE 
 
CLONOGENIC 
 
MULTIPOTENT 
 
IN VIVO CARDIAC 
REGENERATIVE 
POTENTIAL 
Beltrami et 
al (2003) 
c-kit+, Lin- , CD34-CD45- Yes Yes, gave rise to 
cardiomyocytes, 
endothelial and 
smooth muscle 
cells in vitro and 
in vivo 
Yes, injected green 
fluorescent protein 
(GFP+), c-kit+ cells 
into the infarcted 
myocardium and 
gave rise to a band 
of regenerating 
myocardium, 
including new 
cardiomyocytes and 
microvasculature. 
Oh et al 
(2003) 
Sca1+ c-kit-CD31+,Lin- CD34- 
CD45-,  
Not cloned Myocyte 
differentiation in 
vivo and in vitro 
Yes, ischemia 
reperfusion injury -
1.5% myocyte 
differentiation in 
infarct border  zone 
Matsuura 
et al (2004) 
Sca1+ c-kit+, CD34+, CD45+,  Not cloned Myocyte 
(beating), 
adipogenic 
osteogenic 
differentiation, in 
vitro 
Not determined 
Martin et al 
(2004) 
SP, Sca1+ Abcg2+ c-kit+/low 
CD31- CD34+/low  CD45-/low   
Not cloned Myocytes 
differentiation (α-
actin+) in vitro 
Not determined 
Pfister et 
al(2005) 
SP, Sca1+ Abcg2+ c-kit+/low 
CD31- CD34+/low CD45-/low 
CD44low/ 
Nkx2.5+Gata-4+, SMA+Desmin+ 
Tie2+ 
Not cloned, 
Colony forming 
units 
Myocyte 
differentiation 
with sarcomeric 
organization and 
spontaneous 
contractions at low 
frequency in vitro 
Not determined 
Tomita et 
al (2005) 
SP  Sca1+, c-kit+ 
CD45-, CD34+ CD44+ Flk-1+, 
Nestin+, Musashi+, Mdr1+ 
cardiosphere 
formation  
Differentiation of 
cardiosphere 
derived cells into 
neurons, glia of 
CNS and PNS 
lineage (in vitro 
and in vivo) and 
beating 
cardiomyocytes 
(in vitro) 
Not determined 
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Chong et 
al. (2011) 
CD44+, CD90+, CD29+, 
SCA1+/PDGFRα+/CD31–
CD105+,Gata5CRE+,Mesp1CRE
+,Oct4+,cMyc+ 
Not cloned Myocyte 
differentiation 
only in vitro 
Not determined 
Messina et 
al (2004) 
Smith et 
al(2007) 
c-kit+, Sca1+, CD34+, KDR/Flk-
1+, CD31+ 
cardiosphere 
formation 
Endothelial and 
beating myocytes 
differentiation, in 
vitro and in vivo 
Yes, gave rise to 
new myocytes and 
capillaries in 
infarcted 
myocardium 
Smart et al. 
(2011) 
Wt1+,GFP+,YFP+,Sca1+, Not cloned Transdifferentiatio
n to 
cardiomyocytes 
with no fusion 
Yes gives 
cardiomyocytes and 
capillaries in 
infarcted 
myocardium 
Langwitz 
et al (2005) 
Morretti et 
al (2006) 
Zhou et al 
(2008)  
Isl-1+, Sca-1-,c-kit-,Flk1+, 
Nkx2.5+  
 
Wt1,GATA-4, Nkx-2.5+,Isl1+ 
Cloned on 
cardiac 
mesodermal  
layer 
Yes Not determined 
 
 
                      
  Not determined 
 
The c-kitpos eCSCs reside throughout the myocardium and have a high density in the atria and 
LV apex (107). c-kitpos eCSCs can be found in a minimum of three different states: i. 
Quiescent undifferentiated cells; ii. Activated cycling undifferentiated cells; and iii. Cycling 
cells that already express transcription factors characteristic of one cardiac cell lineage. The 
first two cellular development states identify cells that can give rise to the three cardiac cell 
types, whereas cells expressing lineage-specific transcription factors probably correspond to 
the so-called transit cells in other systems and are already committed to a specific cell lineage 
(Figure 1.1).    
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Figure 1.1. Schematic representation of the transitional sequence of cardiac stem-progenitor 
cell committed progeny. Quiescent, primitive, undifferentiated eCSCs express Oct-4 (red 
fluorescence), are activated, and start expressing c-kit (green fluorescence). In response to 
stress, these cells multiply and lose expression of Oct-4. The resulting c-kitpos eCSCs are still 
uncommitted to one specific cardiac cell lineage. After further expansion and differentiation, 
the cells induce expression of transcription factors specific to one cardiac lineage (GATA4, 
ETS1, or GATA6) and differentiate into one of the three cardiac cell types: cardiomyocytes, 
endothelial, and smooth muscle cells, respectively. These newly formed cardiac cells can 
undergo a few rounds of replication before becoming terminally differentiated. 
Abbreviations: α-sarc: alpha sarcomeric actin; CSC: cardiac stem cell; vW-FVIII: von 
Willebrand factor VIII. (Adapted from GM Ellison et al 2006). 
The c-kitpos eCSCs can be isolated and amplified in vitro so regenerative protocols of cell 
transplantation could be employed to treat damaged myocardium. There are two methods of 
isolating these cells; the first technique involves the enzymatic digestion and mechanical 
dissociation of cardiac tissue yielding the small cell population from which eCSCs can be 
purified with antibody selection procedures. The second technique as been described by 
Smits for c-kit and Sca-1 cells, involves the explant culture of pieces of myocardial biopsy 
from which cells migrate from the explant and eCSCs can be purified from these explant-
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derived cells using antibody selection procedures similar as the techniques used for the Sca-1 
derived cells (108).  
1.3.2 Sca-1pos and Side Population (SP) cardiac stem-progenitor cells. 
Stem cell antigen (Sca-1) is a member of the Ly-6 family and an important surface marker for 
somatic cells and especially hematopoietic stem cells (109). This stem cell antigen has been 
used as a marker in the adult heart when isolate progenitor cardiac stem cells in conjunction 
with SP cells and other stem cell antigens like c-kit,CD45,CD34 (101). A number of 
heterogeneous subpopulation of Sca1+ Cardiac Progenitor Cells (CPCs) has been described 
based on the different subset of stem cell markers co-expressed with Sca1.These Sca1+ 
CD31+ cardiac progenitors were identified in the mouse adult myocardium (96) as small 
interstitial cells c-kit-, CD31+, Lin-, CD34-, and CD45-. 
In the above study it has been found that the Sca1+ CD31+ progenitors, express initially 
cardiogenic transcription factors as Gata 4, MEF2C, TEF-1 and when stimulated in vitro with 
5-azacytidine they can acquire a phenotype of cardiomyocytes and can express structural 
cardiac genes. When stimulate in vitro the cardiac Sca1+,c-kit+,CD45+,and CD34+ CPCs with 
oxytocin it could result in the generation of beating cardiomyocytes, and in these conditions 
Sca1+ CD45- could differentiate towards osteogenic and adipogenic lineages showing the 
multipotency of these CPCs (101).  When these cells examined in vivo in the murine model 
the transplanted Sca-1+, CD31- CPCs had beneficial effect on the cardiac remodelling 
following myocardial infarction and seems that they promote regeneration via paracrine 
effects to the local myocardial damaged tissue (110).  
Although other studies have since reported their presence in the human myocardium (111); 
the homology/phenotype of the cells initially identified in the mouse has not yet been 
confirmed in any other species. Sca-1pos have significant overlap and co-expression of 
transcription factors that other cardiac stem-progenitor cells expressed like the  c-kitpos 
18 
 
eCSCs, SP cells etc. (see Table 1.1), and although they show potential as a source of cells for 
cardiac regeneration more studies  required for  further characterisation.  
Side population (SP) stem progenitor cells were first identified in the murine bone marrow by 
their ability to extrude Hoechst dye 33342 (112). This property is attributable to expression of 
ATP binding cassette transporters ABCG2 and MDR1.The existence of SP in the heart was 
first reported in the post-natal murine myocardium where resident verapamil-sensitive SP 
cells with stem cell  activity and cadiomyocyte differentiation potential were detected by 
Hierlihy (92). These cardiac SP cells are highly positive for Sca-1 and low expression of c-
kit, CD34 and CD45. They are negative for CD31 indicating that these SP cells differ from 
the Sca-1pos cells described by Oh in (96). They cells were capable of differentiation into a 
cardiomyocyte phenotype after co-culturing with primary  cardiomyocytes  (92) or as 
recently reported (113) in order to induce differentiation into cardiomyocytes, these cells 
were cultured with various growth factors, such as BMP2, BMP4, and Oxytocin, or on the 
feeder layers of the mesenchymal cells. Only treatment with Oxytocin was able to induce 
Cardiac SP cells into beating cardiomyocytes.  In addition Pfister (98) demonstrated that 
among cardiac SP cells the greatest potential for cardiomyocyte differentiation is restricted to 
cells negative for CD31 but positive for Sca-1.  
These cells showed a potent in vivo activity as their transplantation of Sca-1+ CD31- cells 
into the acutely infarcted mouse heart lead to myocardial regeneration and significant 
improvement in cardiac function (110).In addition the cardiac Sca1+/CD31- SP in a different 
study showed to migrate into the damaged myocardium and to differentiate into 
cardiomyocytes or endothelial cells upon modulation of the SDF-1a/CXCR4 system (114).   
These cells are heterogeneous in nature have distinct subpopulations identified by expression 
of VE-cadherin, CD31,CD34,Sca1 and consisting of vascular endothelial cells, smooth 
muscle cells and mesenchymal progenitors including cardiomyocyte precursors (115). 
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However despite the apparent cardiovascular potential there is not absolute proof that cardiac 
SP cells are a bona fide stem cell population defined by clonogenic and self-renewal 
properties has not yet been provided. 
1.3.3. Cardiosphere-derived cells.  
Cardiospheres are clusters of heterogeneous cells that are exclusively heart derived (116). 
The heterogeneity of the cardiospheres results in a microenvironment that mimics the stem 
cell niche with peripheral supporting cell populations (117). Primary cardiospheres are 
derived from endomyocardial biopsies that are partially digested enzymatically then plated on 
fibronectin coated dishes. After several days in culture small phase bright cells migrate out 
from the explant and these cells form cardiospheres in suspension (118). Cardiosphere cells 
are positive for c-kit, Nkx2.5, desmin connexin 43, KDR, and Isl-1 (116). Cardiospheres can 
be mechanically disaggregated and plated as monolayers, where they are termed 
cardiosphere-derived cells (CDCs), and when exposed to EGF can reform secondary 
cardiospheres. Cardiospheres secrete a number of factors like VEGF, HGF and IGF-I, giving 
them a paracrine role in enhancing regeneration (118). However, there are safety concerns 
associated with the administration of the cardiospheres via intracoronary infusion and the 
potential for adverse events as coronary microembolism. Therefore, the CDCs are viewed as 
a favourable alternative (119).  
1.3.4. Epicardial derived progenitor cells (EPDCs).  
Recently epicardial-derived progenitor cells (EPDCs) have been suggested as a population of 
cells with possible cardiogenic potential. Adult mouse EPDCs induced to express Wilm’s 
tumor 1 (Wt is a key embryonic epicardial gene) through pre-treatment (priming) with 
thymosin β4 (Τβ4), an actin monomer binding protein, can result in neovascularization and 
de novo cardiogenesis, after myocardial infarction. Wt1pos EPDCs are positive for Sca-1 
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(~80%) and co-express early cardiac progenitor markers Isl-1, Nkx2.5 and Gata-4, but were 
negative for c-kit (120). 
Human-derived EPDCs differentiate into endothelial and smooth muscle cells but not 
cardiomyocytes (121). However, they have been shown to improve cardiac function after 
transplantation following an infarct through paracrine protection of the surrounding tissue 
(122). These results identify EPDCs as candidate cardiac stem-progenitors in the adult heart 
and lay the foundation for future efforts to harness the cardiogenic potential of these 
progenitors for cardiac regeneration and repair. 
1.3.5. Isl-1pos cardiac progenitor cells. 
The heart is formed from cardiogenic progenitors expressing the transcription factors Nkx2-5 
and Isl-1(114).  These multi-potent progenitors give rise to the major lineages of the mature 
heart; cardiomyocytes, smooth muscle and endothelial cells (129). Isl-1 cardiac progenitor 
cells are found in the second (anterior) heart field during development and play a crucial role 
in creation of the right ventricle, atria and outflow tract during the embryogenesis of the 
cardiac chambers (130). These progenitor cells could be optimal cells for myocardial 
regeneration, however the presence of Isl-1pos cardiac progenitors is correlated with age, 
where the embryonic heart has abundant levels of Isl-1pos cells, but these reduce in neonatal, 
and are almost absent in adult heart (131). 
1.4 Clinical potential of cardiac stem-progenitor cells. 
Endogenous, cardiac stem-progenitor cells have already been used in phase I clinical trials 
(SCIPIO, ALCADIA, TICAP and ALLSTAR) in which they have been shown to contribute 
to myocardial regeneration. These studies are based on the concept that the eCSCs can trigger 
regeneration of the damaged myocardium that they belong to. They have a number of 
advantages in comparison to other cells such as BMSC, MSC, ESC etc. in that they have a 
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relationship with the cardiac milieu and the fact that their regenerative potential can be 
triggered in situ via paracrine signals from the damaged myocardium (29). In the trials 
described below, the feasibility and safety of the use of these cells is described. 
1.4.1 Autologous cell transplantation. 
Patients with post-infarction LV dysfunction (ejection fraction [EF] ≤40%) before coronary 
artery bypass grafting were enrolled into the SCIPIO TRIAL. One million autologous c-kitpos 
CSCs were administered by intracoronary infusion ~113 days after surgery. 16 patients were 
assigned to the treatment group and seven to the control group; no CSC-related adverse 
effects were reported. In 14 CSC-treated patients who were analysed, LVEF increased from 
30.3% before CSC infusion, to 38.5% at 4 months after infusion. Importantly, the effects of 
CSCs were even more pronounced at 1 year in eight patients with LVEF increasing by 12.3 
ejection fraction units. In contrast on the 7 control patients group during the corresponding 
time interval LVEF didn’t change 30.1% at 4 months after CABG and 30.2% at 8 months 
respectively. A reduction in infarct size was also noted using the semi-quantitative infarct 
score index which was confirmed the echocardiographic analysis. Cardiac MRI showed a 
reduction in mean infarct weight from 32.6g before infusion of the CSCs to 24.8g (24% 
reduction) in 4 months and 22.8g (30% reduction) at 6 months respectively. By contrast in  
the control group there were no significant change in the regional wall motion score index at 
4 months after baseline either in the infarcted LV segments (1.99vs 1.91) at baseline with 
p=0.144 or in all LV segments combined (1.89 vs 1.88) at baseline p=0.846 (128). 
The CADUCEUS TRIAL similarly used intracoronary administered CDCs for heart 
regeneration after myocardial infarction. Patients assigned to receive CDCs received 
autologous CDCs derived from endomyocardial biopsy specimens, which were infused into 
the infarct-related artery 1.5-3 months after myocardial infarction. Four patients (24%) in the 
CDCs group had serious adverse events compared with one control (13%; p=1.00). 
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Compared with controls at 6 months, MRI analysis of patients treated with CDCs showed 
reductions in scar mass, increases in viable heart mass, regional contractility and regional 
systolic wall thickness. However, changes in end-diastolic volume, end-systolic volume and 
LVEF were not different between the two groups at 6 months (120). 
The ALCADIA trial was designed to test the efficacy of transplanting both CSCs from 
endomyocardial biopsies and hydrogel infused with FGF. Injected cells expanded for this 
trial expressed CD105, CD90, CD29, Nanog, Oct 4 and Gata4 and were negative for CD45. 
Data of seven patients after combination therapy at 6 months reported an improvement in 
LVEF from 26% to 35.8% by 3D echocardiography, and 22.6% to 34.7% by MRI. Findings 
also showed a decrease in infarct volume by 23% to 19.7% and a concomitant decrease in 
wall motion score from 17.2 to 6.6. Recently these authors presented their results after one 
year in the AHA meeting in Los Angeles USA, and concluded that transplantation of human 
cardiac derived stem cell with controlled release of bFGF is safe and feasible to ischemic 
cardiomyopathy patients. They suggested that it is a novel biotherapy and it may have a 
potential to restore the injured heart to functional repair with reconstruction of post ischemic 
environment (129).  
In the TICAP trial, transcoronary infusion of cardiac progenitor cardiosphere derived cells 
(CDCs) in patients with a single ventricle was designed to treat hypoplastic left heart 
syndrome in patients less than 6 years old. Phase I consisted of a safety and feasibility trial in 
which fourteen patients received 0.3 million cells/kg of autologous cardiac progenitor cells 
via intracoronary delivery one month after cardiac surgery. Patients were monitored for 3 
months to 1 year after cell transplantation TICAP trial (130). The results of the Phase I trial 
have been released and no complications have been reported, including cardiac death, 
myocardial ischemia, pro-arrhythmia, hospitalization for heart failure, or tumor formation, 
within 24 months of CDC infusion. Echocardiography showed that improvement of right 
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ventricular ejection fraction (RVEF) was greater in the CDC-treated group (+5.3±3.2%) than 
in controls (+0.1±3.4%, P=0.01) at 3 months after CDC infusion. This cardiac function 
enhancement was manifested even 1 year and 2 years after CDC infusion (+7.8±4.9% vs. 
+2.2±3.1% at 1 year, P=0.03; +8.8±3.7% vs. +3.4±6.4% at 2 years, P=0.04). In addition, 
RVEF measured by cardiac MRI was also markedly improved in CDC-treated patients from 
36.1±7.5% at baseline to 42.7±8.7% at 1 year (P=0.04) and to 42.4±7.7% at 2 years 
(P=0.047). The Phase I study concludes that intracoronary infusion of autologous CDCs is 
feasible and safe to treat children with Hypoplastic Left Heart Syndrome (HLHS). This novel 
therapeutic strategy may impact on cardiac function, clinical symptoms of heart failure and 
somatic growth in long-term recovery.  The Phase II of the same trail which has been called 
PERSEUS is now underway and will investigate the efficacy of cell transplantation as the 
primary endpoint. Cardiac ejection fraction will be assessed by echocardiography and 
ventriculography and cardiac MRI will be conducted before and after treatment between the 
control (non-transplanted) and the transplanted treated patients. This phase II trial is due to 
conclude in March 2018.  
The ALLSTAR (allogeneic heart stems cells to achieve myocardial regeneration) trial is 
designed to test safety of allogeneic CDCs. This study is currently recruiting participants with 
LVEF<45% and expects enrolment of 274 patients. 25 million cardiosphere derived cells 
(CAP-1002) will be delivered with intracoronary infusion in  these patients which will be 
compared  with a control group .The CDCs  will be transplanted <3 months or 3-12 months 
after myocardial infarction to assess the ideal time frame for cell delivery. This is the first 
trial to assess allogeneic use of cardiac stem-progenitor cells in humans ALLSTAR TRIAL 
(131).The study is still undergoing and still recruiting participants with completion date the 
December 2015. Until now no interim results have been published or presented in the 
literature. 
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1.4.2 Autologous regeneration without cell transplantation. 
Transplantation of autologous stem cells is a long and expensive procedure still in its relative 
infancy and is not available to all patients who require regenerative therapy for their damaged 
myocardium. Given that the eCSCs express receptors for transduction pathways relating to 
various growth factors i.e. Insulin like growth factor I (IGF-I), hepatocyte growth factor 
(HGF), a new concept has emerged to stimulate endogenous repair and regeneration 
mechanisms in vivo, without the need for cell transplantation. This concept has already been 
demonstrated in rodent trials, proving to be very effective in producing myocardial 
regeneration after MI in mice (132). To prove this concept in larger mammals, a recent study 
was conducted by Ellison (27), firstly identified c-kitpos eCSCs in the adult pig myocardium, 
which possess stem cell properties i.e. clonogenicity, multipotency and self-renewal. The 
porcine c-kitpos eCSCs expressed receptors for IGF-I and HGF and responded to stimulation 
with IGF-I and HGF via downstream effectors in vitro, increasing c-kitpos eCSC proliferation, 
migration and cardiomyogenic differentiation.   
Subsequently, IGF-I and HGF (2 to 8µg IGF-I and 0.5 to 2µg HGF), were administered via 
intracoronary injection, just below the site of left anterior descendent occlusion, 30 minutes 
after Acute Myocardial Infarction (AMI) during coronary reperfusion. IGF-I/HGF in a dose-
dependent manner improved cardiomyocyte survival and reduced fibrosis with 
cardiomyocyte reactive hypertrophy. Furthermore, this growth factor cocktail triggered a 
regenerative response from the c-kitpos eCSCs, without the need for cell transplantation (27). 
Histological changes were correlated with a reduced infarct size and an improved ventricular 
segmental contractility and ejection fraction at the 2 month follow-up assessed by cardiac 
MRI.  
1.5 c-kitpos eCSCs within the four cardiac chambers. 
1.5.1 The c-kitpos CD45neg eCSC niche. 
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The c-kitpos eCSCs reside in potential stem cell niches, which provide a stable 
microenvironment designed to preserve the survival and replication potential of stem cells 
(133). In cardiac niches, c-kitpos eCSCs are regulated by the surrounding cellular and non-
cellular constituents. The niches are located more in areas of less stress like the atria and LV 
apex, meaning exposed to moderate and minimal mechanical forces in the anatomic 
components of the heart (134). In contrary the base and mid-region of the heart have high 
stress areas due to the organization of the myocyte bundles and the level of the mechanical 
forces. CSC niches have been identified by Urbanek (132) and their role has been assumed to 
be related as a reserve cells to support regeneration of the damaged tissues. The general trend 
of the niches is to reserve a local milieu of  quiescent eCSCs cells that can be activated when  
needed  in the myocardium  and they can be mobilised and stimulate regeneration after 
production of paracrine stimulation of the local endogenous cells or even distant cells in 
different  cardiac chambers. The c-kitpos eCSCs can undergo either symmetric (one eCSC 
gives rise to two eCSCs) or asymmetric (one eCSC gives rise to one eCSC and one 
committed cell) division as shown in vivo in the mouse model by Cesselli (134), are 
reportedly dynamic in their function and can be mobilized to areas of injury soon after 
infarction (135).  
Data suggest that the atrial appendages in humans are rich in cardiac progenitors (136). 
Studies by Itzhaki (137) identified a number of cell niches in the right atrium a chamber rich 
of eCSCs positive of c-kit and Isl-1. Completing the recent evidence by the group of Arsalan 
is been reported that the left atrium contained viable numbers of eCSCs too (105). Studies by 
Castaldo (138) identified the presence of CD117 positive cells localized in the sub-
epicardium, and their activation was associated with Laminin-1 and alpha-6 integrin 
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expression. Interestingly it has been demonstrated that cardiac progenitor cells exist in the 
right atria of the sheep (104).  
To date very few studies have interrogated the presence of eCSCs in the human myocardium 
and no studies have investigated their profile in terms of their chamber of origin nor 
correlated them with the primary and secondary heart field. This will be one objective of this 
thesis and will be explored in the next paragraphs. 
1.5.2 Embryological heart development. 
 
In mammals the development and morphogenesis of the cardiac chambers is under the 
control of chamber-specific genetic programs. In the adult, these differences in gene 
expression result in cardiac muscle (particularly between atria & ventricles) with different 
biochemical, contractile and functional properties (139). In animal hearts (mouse and chick) 
at the embryological level, a number of transcripts have been identified and mark the 
evolution and genotypic mapping of each chamber accordingly to the evolution stage. 
Primarily the ballooning theory of the embryological origin of the heart gave a new insight 
into heart chamber development and the genes that are expressed throughout the process of 
the development of each chamber see Table 1.2 (140,141). 
Table 1.2 General and specific transcription factors from each chamber depending on 
the stage of cardiac embryogenesis according to the ballooning theory (Adapted from 
Moorman et al 2003). 
Chamber of  Origin Early Medium Late 
Atrial    
RIGHT ATRIUM 
GATA 4,5,6 
Retinoic acid  
(Raldh2) 
ANF , TBX-5, 
MLC-2a 
CX40, CX43, Hrt1 
 Tbx-20   
LEFT ATRIUM Tbx-20 TBX-5 CX40, CX43 
 Retinoic acid 
 
Hesr1,  MLC-2a 
 
Pitx-2, Hrt1 
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1.5.3 The primary and secondary heart field. 
 
The recent theory of the primary and secondary heart fields (142,143,144) challenged the 
embryological origin of the 4 cardiac chambers and their topographical genotypic location. It 
is important to point out that the identification of transcripts for the origin of each chamber 
and heart field have been made in mouse but not in human see Figure 1.2. 
 
Figure 1.2 Transcriptors expressed according to primary and secondary heart fields (Adapted 
from Srivastava et al 2009). 
Ventricular    
RIGHT VENTRICLE 
SERCA-2,  MLC-
2v,  Isl-1 
Hand-2, GIN-2 Hand-2, GIN-2 
 Hrt2 Mlclv-nlacZ-24 CX43 
LEFT VENTRICLE SERCA-2, MLC-2v Hand-1 Hand-1, IRX4 
 
 
 
Hrt2 
TBX-5 
 
Mlc3f-nlacZ-2 
TBX-5 
 
CX43 
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This theory suggested that later in embryogenesis and in adult life there is a consistent 
phenotypic pattern and function of all the cardiac chambers. A mutation in these genes can 
give an abnormal phenotype of the cardiac chamber and in consequence abnormal function of 
the cardiac muscle or the valve apparatus. As mentioned earlier these recent studies have 
demonstrated that the cardiogenic mesoderm maintains two multi-potent progenitor cell 
populations known as first heart field (FHF) and secondary heart field (SHF) which give rise 
to various cardiac structures. The FHF originates in the anterior splanchnic mesoderm and 
forms the cardiac crescent from which cells migrate medially to form the linear heart tube. 
Ultimately the FHF contributes to left ventricle (LV) (127,144,145), while the SHF which 
originates in the pharyngeal mesoderm medial to the cardiac crescent and lies anterior and 
dorsal to the linear heart tube contributes to the right ventricle (RV) and outflow tract and 
both atrial tissues, accounting for two thirds of all the cells in the heart (146). While not all 
genetic markers unique to the FHF and SHF have been identified, some transcription factors 
and signalling molecules are known to characterise each population. Both heart fields are 
marked by the homeobox protein Nkx-2.5, but the FHF progenitors are distinguished by the 
expression of the T-box transcription factors such as Tbx5 and Tbx20 and the basic helix-
loop-helix (bHLH) transcription factor, and Heart and neural crest derivatives expressed 
protein-1 (Hand1). The SHF progenitors contribute to the formation of all the chambers 
except the LV (which is formed by the FHF) and are distinguished by Insulin gene enhancer 
protein-1 (Isl-1), Heart and neural crest derivatives expressed protein-2 (Hand2), Tbx1, 
Forkhead  box protein H1 (FoxH1), Fibroblast growth factor 8 (Fgf8), and Fibroblast growth 
factor 10 (Fgf10),(142) (see Table 1.3). Although a retrospective clonal analysis in the mouse 
embryo suggested the FHF and SHF progenitors originate from a common precursor (147), 
further investigations must be pursued in order to determine whether the FHF and SHF 
progenitors stem from a single precursor or perhaps a subset of precursors (148).  
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Table 1.3 Transcripts from primary & secondary heart fields. Mutants of these genes are 
responsible for congenital cardiac pathologies as shown on the left of the table. OFT: outflow 
tract, INF: inflow tract, LV: left ventricle, RV: right ventricle, A: atria (Adapted from 
Buckingham et al, 2005). 
Transcript 
Crescent 
expression 
Second 
heart field 
expression 
Cardiac 
tube 
expression 
Mutant phenotype in the cardiac tube 
Nkx-2-5 yes yes yes 
Single atrial and ventricular compartment Loss 
of ventricular tissue, no Hand 1 expression 
Hand1 yes no 
LV (high in 
outer 
curvature) 
LV Disrupted 
TBX-5 yes no LV ,A, INF Sino-atrial defects; Hypoplastic LV 
Fgf10 no yes no No early phenotype detected 
Fgf8 no  yes no OFT Defects 
TBX1 yes yes no OFT Defects 
Isl1 no yes 
OFT, RV, LV, 
A, INF 
Single atrial and ventricular compartments; no 
OFT; Hand 1 and TBX-5 expression which 
indicates that LV identity is intact; atria at the 
venous pole abnormal 
Foxh1 no yes no OFT reduced or absent; RV doesn’t develop 
Mef2c yes yes yes 
OFT reduced; RV doesn’t develop(HAND2 down 
regulated) 
INF abnormalities 
Hand2  yes yes RV RV Abnormalities 
TBX-20 yes yes OFT,RV,LV 
Chambers do not develop, no  Hand 1 
expression; hypoplastic RV; OFT disrupted 
 
The classification of these two cardiac heart fields simplifies the embryological origin of each 
chamber and suggests that transcripts that are specific for each chamber could be used as 
markers of recognition for the eCSCs that reside in each chamber to identify their origin.  
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1.5.4 Do c-kitpos eCSCs reflect their chamber of origin? 
As mentioned previously, c-kitpos eCSCs cells reside in all chambers of the myocardium and 
are most prevalently in the LA, RA and LV apex, and less prevalent in areas of higher stress 
such as the mid-base region of the LV (107). Two recent studies have identified in the murine 
(149) and human (105) heart that the maximum number of c-kitpos eCSCs reside in the LA. 
However, no studies have explored whether their transcriptional profile is related to their 
embryological origin, being reflective of the chamber where they reside in. Therefore, are c-
kitpos eCSCs chamber specific, expressing a transcriptional profile reflective of the chamber 
in which they reside and were isolated from, or do c-kitpos eCSCs express a generic, global 
transcriptional profile, encompassing transcripts reflective of all cardiac chambers?  The 
answer to this question is critical when it comes to whether c-kitpos eCSCs can be used for 
regenerative therapies. Indeed, this information is of a significant biological and clinical 
significance because if the c-kitpos eCSCs are remnants of the chamber anlagen and reflect 
their chamber of origin, it is likely that they would also generate the corresponding tissue (i.e. 
right atria eCSCs give raise to right atria cardiomyocytes). Therefore cell transplantation 
therapy could run the risk of producing inappropriate myocardium, giving rise to arrhythmias 
or regional wall abnormalities. It is the LV myocardium which is damaged in Myocardial 
Infarction (MI) and needs to be replaced using stem cell therapy. If on the other hand, the c-
kitpos eCSCs are indistinguishable and interchangeable throughout the myocardium, then their 
source for cell therapy becomes simpler and the right atrial appendix which is the easily 
accessible and obtainable becomes the source of choice. With this information in hand the 
most optimal myocardial regeneration strategies, either through direct cell transplantation or 
in situ activation of c-kitpos eCSCs post MI, can be applied to treat cardiac failure and 
regenerate the damaged myocardium. 
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1.6 Objectives & hypotheses. 
The first objective of this thesis is to isolate c-kitpos eCSCs from all 4 cardiac chambers of the 
human heart and compare the number of c-kitpos eCSCs isolated between chambers. Due to 
the high prevalence of c-kitpos eCSCs in the atria and LV apex and low number in the RV and 
LV mid-base region reported in the literature, it is hypothesized that more c-kitpos eCSCs will 
be successfully isolated from the left and right atria and fewer obtained from the LV base  
and RV samples. The LV samples, as shown in previous studies, have a different distribution 
of cardiac stem cells throughout the myocardium with higher number on the LV apex and 
atria and fewer at the base of the heart. In this study the size of the LV and RV samples were 
small as a consequence of these areas of harvesting being vulnerable areas of bleeding and 
thus running the risk of compromising the patient safety.  
The second objective of this thesis is to characterize the transcriptional profile of c-kitpos 
eCSCs isolated from all four chambers using quantitative real time polymerase chain reaction 
(qRT-PCR) to assess expression of genes specific to the first and second heart field and to 
determine whether the transcriptional profile of these cells is related to their chamber of 
origin. It is hypothesized that eCSCs isolated form the 4 chambers of the human heart would 
have a universal transcriptional profile rather than a profile that reflects their chamber of 
origin. This would give the added advantage of being able to isolate c-kitpos eCSCs from any 
of the four cardiac chambers to produce cardiomyocytes that exhibit specific characteristics 
of the chamber that they are required to regenerate. This will increase their viability for future 
cell therapy in patients with cardiac disease. 
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2. MATERIALS & EXPERIMENTAL METHODS 
2.1 Cardiac sample/biopsy collection. 
Between August 2011 and April 2012, small pieces of myocardium (0.189 ±0.22g) were 
obtained from all 4 chambers of the adult human heart of fully consented patients (male & 
female, >18 years and < 90 years, n=5 for each cardiac chamber) undergoing cardiac surgery 
at the Liverpool Heart & Chest Hospital (LHCH), Liverpool, United Kingdom. Ethical 
approval for these procedures was given by NREC (08/H1306/91; PI, Dr. G.M Ellison) and 
local R&D LHCH ethical approval. Upon arrival at the laboratory the sample was weighed 
and photographed before proceeding immediately to cell isolation (Figure 2.1).   
 
Figure 2.1 Example sample before enzymatic isolation of cells. 
 
2.2 Small cell isolation by enzymatic digestion.  
Cardiac small cells were isolated from human myocardial samples by enzymatic digestion. 
The sample was cut with sterile scissors into very small pieces (~1-2mm) inside a small, 
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25ml conical flask containing 15mls of Collagenase type 2 Worthington® 1mg/ml in DMEM 
(Figure 2.2).  
 
Figure 2.2 Photographs showing a myocardial sample in a conical flask before cutting (left) 
and after sufficient cutting (right); notice the small size (less than 1-2mm) of the pieces after 
cutting as shown inside the red box for been noticeable. 
A small magnetic stir bar was placed into the conical flask, which was transferred to a 37°C 
oven on a stirrer plate set at 250 RPM for 5 min, to further dissociate the tissue. The 
supernatant was transferred to a 15ml falcon tube and centrifuged at 300G for 5 min. After 
centrifugation, the pellet was re-suspended in 10ml of 10% foetal bovine serum (FBS) in 
DMEM and left on ice. A further 15ml of 1mg/ml Collagenase type 2 Worthington® in 
DMEM was added to the conical flask containing the sample sediment and returned to the 
37°C oven to continue mixing. This process was continued every 5 min for a further 10-15 
times or until complete digestion of the tissue. When the digestion process was completed all 
the re-suspended cell pellets were combined and passed through a 40 micron filter into a 
50ml falcon tube and centrifuged for 7 min at 400G. The pooled pellet was re-suspended in 
3ml of DMEM and the number of viable small cells were determined using a 
haemocytometer and trypan blue stain. To perform cell counts, 10µl of undiluted cell 
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suspension was mixed with 10µl of Trypan blue to identify dead/non-viable cells and loaded 
onto the haemocytometer. Clear bright cells were counted in four of the 1mm² squares and 
the average taken to determine the number of viable cells in 100µl (0.1mm³). This value was 
multiplied by 2 to account for the 50% dilution with Trypan blue and then multiplied by 
10000 to determine the number of viable cells per cm³ or per ml (150). The total number of 
cells isolated were calculated before (cardiac small cells) and after MACS separation (c-kitpos 
cardiac stem-progenitor cells). The number of cells per gram of tissue was calculated for each 
cardiac sample and used to determine average number of cells per gram of tissue for each 
cardiac chamber.  
2.3 c-kitpos cardiac stem-progenitor cell isolation. 
The c-kitpos endogenous cardiac stem/progenitor cells (eCSCs) were purified from the small 
cell population by magnetic activated microimmunobead sorting (MACS; Miltenyi®), 
according to the manufacturers protocol (Figure 2.3). The cell suspension was centrifuged at 
300G for 10 min, supernatant removed and the cell pellet re-suspended in 300µl of incubation 
media (DPBS 492mls, Bovine Serum Albumin 2.5gr, Fungizone 500µl, Gentamycin 500µl, 
Pen/Strep 5mls, and EDTA 2mls). After adding 100µl of FcR Blocking reagent (MACS, 
Miltenyi® Biotec) and 100µl CD117 microbeads (MACS, Miltenyi® Biotec), the suspension 
was mixed for 15 min at 4°C. After washing the cells by adding 1ml of incubation media, 
centrifugation of the cells at 300G for 10 min was performed. 
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Figure 2.3 Photographic representation of MACS technology (MACS; Miltenyi®) of c-kitpos 
CSCs from the cardiac small cells. Magnetically labelled (c-kitpos) cells are retained in the 
column by the magnet while unlabelled (c-kitneg) cells pass through into the collection tube of 
15mls on the left of the picture. 
 
The magnetic MS column was rinsed with 500µl incubation media, before passing the cell 
suspension through the column. The unlabelled cell fraction (c-kitneg) was collected in the 
flow through and discarded. Then the column was washed three times with 500µl of 
incubation media. The column was removed from the magnet and 1ml of incubation buffer 
was added to the column and was immediately flushed with the plunger into a fresh 
collection tube and the magnetically labelled (c-kitpos) cells were collected (Figure 2.4).  
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Figure 2.4 Diagrammatic representation of the isolation of c-kitpos eCSCs (Adapted from 
www.miltenybiotec.com).  
 
The c-kitpos population was centrifuged for 3 min at 1300 rpm, the supernatant removed and 
the pellet re-suspended in growth media (see below for recipe) and plated for cell culture. 
2.4 Cell Culture. 
Human c-kitpos eCSCs were plated onto gelatin coated 12-well plates (BD) in  human eCSC 
growth media [DMEM/F12K (Gibco) supplemented with 10% FBS-ESQ, 10 ng/ml bFGF 
and 10 ng/ml LIF, 1% NAAA, 1/% Glutathione, 0.005U/ml  hEPO (sigma) and antibiotics 
(1% Pen/strep, 0.1 % Fungizone & 0.1% Gentamycin (10mg/ml liquid Invitrogen). Cells 
were cultured at 37°C on 2% O2 and 5 % CO2 for up to 2-3 weeks. Media was changed after 5 
days, and then every 2-3 days thereafter. 70% of the media was removed and replaced with 
fresh media to enable cells to condition their media through the secretion of growth factors 
and cytokines that benefit their own growth and proliferation. When ~1 x 106 cells had been 
propagated (usually after 2 weeks), cells were trypsinised and lysed for total RNA isolation. 
The population of c-kitpos CD45- cells were collected after 2 weeks of culture. The c-kitpos 
CD45+ cells, such as mast cells, which do not grow in adherent culture conditions they have 
been discarded.  
    c-kit 
c-kitpos c-kit
neg 
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Upon reaching full confluency the cells were harvested as follows: media was aspirated and 
the adherent cell monolayer washed with 5mls of phosphate buffered saline 
(PBS+Antibiotics) at room temperature to remove residual protein or dead, detached cells. 
PBS+ABs was removed and replaced with 2mls of trypsin. Trypsinization was performed at 
37°C for ~5 min. Cell detachment was monitored using transmitted light microscopy 
(Olympus®, CKX 41 Japan) until approximately 90% of cells had detached, at which point 
the trypsin was neutralised by addition of 6 mls of serum-rich passaging media [10% fetal 
bovine serum (FBS) in DMEM].  The trypsin/cell suspension was transferred to a 15ml 
falcon tube and centrifuged at 1300g for 3 min at 25°C to pellet the cells. The resulting 
supernatant was aspirated and the remaining cell pellet lysed in 350µl of RLT buffer* with 
the addition of 10µl 1M β-mercaptoethanol (Sigma-Aldrich) for 5 min at room temperature 
before being transferred to a QIA shredder column (Qiagen®) and centrifuged at 12000RPM 
for 2 min.  The resulting lysate was stored at -80°C until further analyses.  
*RLT is a lysis buffer which contains a high concentration of guanidine isothiocycanate, which supports the binding of RNA 
to the silica membrane for lysing cells and tissues prior to RNA isolation and simultaneous RNA/DNA/Protein isolation 
from (Qiagen)®. 
2.5 RNA isolation. 
At all stages gloves were worn, and filtered, DNase-RNase free pipette tips (Rainin) were 
used. All equipment was cleaned thoroughly with ethanol before and throughout the 
procedure. Total RNA was isolated from cell lysates using an RNeasy mini-kit (Qiagen®), 
according to the manufacturer’s protocol. The lysate was removed from the -80°C freezer and 
placed in a 37°C water bath to thaw. When fully thawed, 700µl (or equal part volume to 
lysate) of 70% molecular grade ethanol was added and mixed well using a micropipette. This 
sample solution was then transferred to an RNeasy mini spin column (pink) and centrifuged 
for 15sec at 10000RPM. The flow through was discarded and the column was then rinsed 
with 350µl of buffer RWI and centrifuged for 15sec at 10000RPM. The flow through was 
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discarded and 10µl of DNase (Qiagen) mixed with 70µl of buffer RDD was added to the 
membrane of the column and left to stand at room temperature for 15 min. This step allowed 
the removal of residual contaminating DNA from the sample. The column was rinsed with 
350µl of buffer RWI and centrifuged for 15sec at 10000RPM. After discarding the flow 
through, 500µl of buffer RPE was added to the column and it was centrifuged for another 15 
sec at 10000RPM. The flow through was discarded and a further 500µl of buffer RPE was 
added and the column was centrifuged for 2 min at 10000RPM. Subsequently, the RNeasy 
spin column was placed into a new 2ml collection tube and centrifuged at full speed at 20000 
RPM for 1 min. This last step was performed to eliminate any possible carryover of buffer 
RPE, or residual flow-through. The RNeasy spin column was next placed in a new 1.5ml 
collection tube and 30µl of RNase free water was applied directly to the column membrane. 
After centrifugation for 1 min at 8000RPM, the total RNA was eluted into the water and 
collected into the 1.5ml tube. The tube containing the RNA sample was kept on ice until 
spectrophotometric analysis with the Nanodrop to determine RNA quantity and quality. 
2.6 Nanodrop spectrophotometric analysis. 
The quantity and purity of the total RNA was determined using a Nanodrop (LabMode 
Washington Delaware USA) spectrophotometer. 2µl of the sample was analysed for the 
purity (260/230 and 260/280 ratios) and quantity (ng/µl) of the RNA. The 260/280 ratio 
shows ethanol or protein contamination of the sample while the 260/230 ratio shows DNA or 
other contamination (Figure 2.5). A ratio < 2.0 is generally accepted as pure for DNA, but a 
ratio of 2 is generally accepted as pure for RNA (151). If the ratio is lower in either case it 
may indicate the presence of protein, phenol or other contaminants that absorb strongly at or 
near 280nm. After quantity and purity Nanodrop assessment, total RNA samples were stored 
at -80°C until processed for cDNA synthesis. 
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Figure 2.5 Nanodrop quantification of RNA quantity and purity. In red circle is the RNA 
concentration of the sample, this is used to calculate the volume of the sample needed for 1µg 
of RNA required for the c-DNA synthesis. In green circle shown the purity ratios of 260/280 
and 260/230 respectively. 
2.7 Reverse transcription or cDNA synthesis. 
Reverse transcription (RT) was performed using a Taqman reverse transcription kit (Applied 
Biosystems) ® on a Biorad I-cycler. For each sample, 1µg of total RNA was required for the 
RT reaction, and the volume of RNA sample needed for 1µg was calculated using the RNA 
concentration determined with the Nanodrop. Each sample was made up to a total volume of 
38.5µl by the addition of RNase free H2O. To each sample, 61.5µl of RT master mix was 
added to make a total volume of 100µl for each RT reaction. The volumes and concentrations 
of the components of the RT master mix are listed in Table 2.1. 
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Table 2.1 Table showing components of reverse transcriptase reaction mixture; (adapted 
from User guide Applied Biosystems Life Biotechnologies, Chapter 3 Reverse 
Transcription). 
REVERSE TRANSCRIPTASE 
REACTION MIX 
  
Component Volume/Tube(µl) Final concentration 
   
RNase free water Variable*  
10xRT Buffer  10 1x 
25mM MgCl2 22 5.5mM 
deoxyNTPs Mixture(2.5mM) 20 500µM per d NTP 
Random Hexamers¹ (50µM) 5 2.5µM 
RNase Inhibitor (20U/L) 2 0.4U/µl 
Multiscribe Reverse Transcriptase 
(50U/µl) 
2.5 1.35U/µl 
Total 61.5**  
*the volume of RNase free water (µl) will be 38.5-RNA sample volume in 100 µL reaction 
¹Random Hexamers, oligo d (T) 16 or sequence specific reverse primers can be used for primers of c-DNA 
synthesis. 
** if changing the reaction volume make sure the final proportions are consistent with the recommended 
values above  
 
Reverse Transcription was performed on a Biorad I cycler as follows:  
a. First step is the hexamer incubation period of 10 minutes at 25°C  
b. Second step is to perform reverse transcriptase for 30 min at 48°C 
c. Last step of 5 min at 95°C to stop the reverse transcriptase reaction.  
The cDNA synthesised from the RT reaction was stored at -80°C for qPCR analysis. 
2.8 Primer design. 
Firstly, coding strand cDNA sequences of genes of interest were identified using the genome 
search platform (www.ncbi.nlm.nih.gov). The Coding DNA sequence (CDS) was copied into 
the primer design program Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast), 
which performs a basic local alignment search of human genome sequence databases to find 
regions of local similarity within sequences. Once a successful BLAST had been performed a 
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primer search was carried out allowing the selection of regions of the coding strand sequence 
suitable for amplification. Primers were designed to range between 20-25bp along with a 
guanine –cytosine (GC) content ranging between 40-60%, and an annealing temperature of 
60.0 ± 3°C. In addition, all primers were designed to span exon-exon junctions to ensure that 
they do not associate with genomic DNA. All primers (Table 2.2) were designed in-house 
and were purchased from Sigma Aldrich. 
Table 2.2 List of qPCR primers used in the study. 
 
SPECIES/GENE 
 
SEQUENCE 
 
cDNA product size 
(bp) 
 
Tm 
 
NCBI Ref Seq 
     
human HRT-1-F CGAGGTGGAGAAGGAGAGTG 177 60 NM 012258.3 
human HRT-1-R CTGGGTACCAGCCTTCTCAG  59.9  
     
human HRT-2-F TGGGGAGCGAGAACAATTAC 181 60.1 NM 012259.2 
human HRT-2-R TCAAAAGCAGTTGGCACAAG  60  
     
human Hand1-F ACATCGCCTACCTGATGGAC 138 60 NM 004821.2 
human Hand1-R GAAAACCTTCGTGCTGCTG  59.6  
     
human Hand2-F ACATCGCCTACCTCATGGAC 162 59.9 NM 021973.2 
human Hand2-R TGGTTTTCTTGTCGTTGCTG  59.9  
     
human Tbx-20-F GCGGCTCTAAGGAGAAGGAG 165 60.6 NM 001077653.2 
human Tbx-20-R TGCACAGAGAGGAGGAGGAC  60.5  
     
human Tbx-5-F TCAAGCTCACCAACAACCAC 150 59.7 NM 000192.3 
human Tbx-5-R CAGGAAAGACGTGAGTGCAG  59.6  
     
human PITX-2-F CTGAGTGCTTGCCAGTATGC 137 59.6 NM 001204399.1 
human PITX-2-R CTTTAGTGCCCACGACCTTC  59.7  
     
human FGF-10-F GAGATGTCCGCTGGAGAAG 194 59.9 NM 004465.1 
 human FGF-10-R TTTCCCCTTCTTGTTCATGG  59.7  
     
human FGF-8-F GTAGGGCACCCAAAACTCAA 117 59.9 NM 001206389.1 
human FGF-8-R AACAGCAAAAACCCAACAGC  60  
     
human ISL-1-F AAACAGGAGCTCCAGCAAAA 157 59.9 NM 0022022 
human ISL-1-R AGCTACAGGACAGGCCAAGA  59.7  
     
human FOXH-1-F AGCCCCCTAAGAGGAGGAAG 134 60 NM 003923.2 
human FOXH-1-R GACCTGACGGATGATCTGGG  59.9  
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2.9  Quantitative Polymerase Chain Reaction (qRT-PCR). 
Quantitative real time polymerase chain reaction (qPCR) allows amplification and 
simultaneous quantification of double stranded DNA. In this study a fluorescent dye (SYBR 
green) which binds double stranded DNA was used to assess PCR reaction kinetics. For each 
gene of interest, a mixture of 10µl of SYBR green, 1µl forward primer, 1µl reverse primer, 
7µl of RNase free H2O and 1µl of cDNA was prepared in triplicate for each sample in a 96 
well plate on ice.  Once setup and plate preparation was complete the plate was sealed with a 
film and centrifuged at 1300rpm for 20 sec at full speed to ensure that all the reagents had 
collected at the bottom of the wells of the PCR plate.  
Plates were transferred to a Biorad® MyIQ thermocycler and qPCR was conducted as 
follows: samples were denatured for 5 min at 95°C followed by 40 cycles of amplification at 
95°C for 15 seconds, 30 seconds at an annealing temperature of 60°C and 30 seconds at 
72°C. Following this, melt curve analysis was performed of 81 cycles on 55-95°C for 30 
seconds each.  
Once amplification had been performed melt curve analysis of the product was undertaken 
where plates were subject to an increase in temperature of 1°C per 30 seconds, starting at 
55°C and terminating at 95°C. The melt curve analysis will identify different reaction 
products and non-specific products. On completing the amplification reaction a melt curve is 
generated. When the double stranded DNA in the reaction denatures the fluorescence 
decreases intensity. As the melting temperature of double stranded DNA varies depending 
upon its base composition, this analysis indicates the identity of the amplified products when 
compared against the melting temperature of an amplified product for a specific primer 
(Figures 2.6a, b). The negative first derivative of the change in fluorescence is plotted as a 
function of temperature (see Figures 2.6a, b). A characteristic peak at the amplicons melting 
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temperature (Tm, the temperature at which 50% of the base pairs of a DNA duplex are 
separated) distinguishes it from other products such as primer-dimers, which melt at different 
temperatures. In the example of the Figures 2.6a, b the Tm of this specific product which 
successfully analysed during qPCR was 82°C.  
 
 
Figures 2.6 (a, b) Example of a melting curve analysis (a) and melting peak chart (b) in one 
of the reactions. Notice that for this specific product the Tm was at 82°C.  
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Ct values were calculated by the MyIQ when fluorescence from SYBR green binding to 
double stranded DNA entered its exponential phase during amplification. All reactions were 
performed in triplicate. Amplicons were stored at 4°C.  
2.10 Quantitative PCR normalisation Algorithm. 
For each gene or transcript relative expression was calculated and normalized to expression 
of the two housekeeping genes GAPDH and beta-Actin using the following equation used as 
our standard reference in our laboratory (152):  
 
 
 
 
2.11 Statistical Analysis. 
Due to the variability of the speciments taken form each patient in order to analyse efficiently 
all the genes expressed from each specimen and from each chamber we used the sequent 
statistical methodology: after correcting for multiple testing and analyse the data on the linear 
model,we checked for normality of the distribution of the the data using the Shapiro-Wilk 
significance value which needed to be (greater than 0.05), and then we used the one-way 
ANOVA with Tukey post hoc tests to locate significant differences.  Significance was set at 
p<0.05. Multiple data are shown as Mean ± SD. 
 
 
 
 
 
 
HKi = GAPDH Ct - (Median GAPDH Ct - Median Actin Ct) 
 
Copy number of target = 2500*1.93^ (HKi - target Ct) 
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3. RESULTS 
3.1 Isolation of c-kitpos eCSCs and their quantity in the four cardiac chambers. 
Cardiac tissue was obtained from consenting patients and the weight of each sample was 
recorded. Endogenous c-kitpos cardiac stem cells (eCSCs) were then isolated following 
enzymatic digestion of the tissue and magnetic-activated cell sorting (MACS).  The number 
of ckitpos cells in each chamber was recorded after their isolation, and the number per gram of 
tissue was calculated. These results are shown in Table 3.1. 
The samples obtained from the RA showed the greatest weight being 0.46±0.36g. However, 
ANOVA analysis revealed no statistical significance between samples for weight (Table 3.1). 
The highest numbers of c-kitpos eCSCs were also isolated from the RA samples 
(4860±2130)/cm3 which is in line with the RA samples being bigger and from the LV 
samples which were more muscular (4626±2945)/cm3. However, ANOVA analysis between 
the LA, RA and LV revealed that there were no significant differences between chambers for 
the number of ckitpos cells isolated. When the number of c-kitpos eCSCs per gram of tissue 
was calculated, the LV showed the greatest number of c-kitpos eCSCs/gram of tissue, however 
similarly to the previous analysis, there were no significant differences detected between 
chambers after the ANOVA analysis (see Table 3.1).  
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Table 3.1 Sample weight, number of c-kitpose eCSCs isolated and number of c-kitpos eCSCs 
per gram of tissue, from all 4 human cardiac chambers accordingly to sex, age and pathology 
of the patients.(AS: aortic stenosis, MS: mitral stenosis, MR: mitral regurgitation, TR: 
tricuspid regurgitation, 3VD: three vessel disease,4VD: four vessel disease).  
Samples Weight 
(gr) 
No of c-kitpos 
isolated/cm3 
No of c-kitpos 
cells/gr of tissue 
Sex Pathology Age p-
value 
LA1 0.123 2700 21951 M MS 77  
LA2 0.147 4275 29082 M MR 68  
LA3 0.086 3600 41860 M MS/TR 73  
LA4 0.086 4400 51163 M 3VD/MS 80  
LA5 0.114 3300 28947 F AS/MR 78  
mean±SD 0.11±0.03 3655±704 34601±11720   75.2±5 NS 
RA1 1 6400 6400 M 3VD 77  
RA2 0.277 1800 6498 M AS/3VD 64  
RA3 0.147 5000 34014 F AS 90  
RA4 0.227 3900 17181 M 4VD 75  
RA5 0.638 7200 11285 F 3VD 74  
mean±SD 0.46±0.36 4860±2130 15076±11470   76±14 NS 
LV1 0.025 3000 120000 M AS 82  
LV2 0.243 9600 39506 M MR 72  
LV3 0.068 3600 52941 M MS/TR 72  
LV4 0.186 4800 25806 F MS 68  
mean±SD 0.18±0.13 4626±2945 49945±42097   73.5±8 NS 
RV1 0.033 2475 75000 M MS/TR 74  
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3.2. Cell morphology of c-kitpos eCSCs isolated from LA, RA, LV, and RV chambers. 
Transmitted light microscopic observations of c-kitpos eCSCs in culture revealed that most of 
the isolated c-kitpos cells were generally small and rounded, consistent with a c-kitpos eCSC 
phenotype.  
All the cells from most of the LA samples showed a uniformly pattern of growth in culture 
without any evidence of change of their phenotype during their culture period. The culture 
period for the c-kitpos eCSCs isolated from the LA was 16.2±2.6 days, before they reached 
full confluence and were lysed for RNA isolation (Figure 3.1). 
c-kitpos eCSCs isolated from the RA were also generally small and rounded with the 
exception of RA5, which appeared more spindle shaped as shown in Figure 3.2. Similar to 
LA, the c-kitpos eCSCs isolated from the RA cells had a mean growth time in culture of 
15.4±3.6 days. With the exception of RA5 that was in culture for 21 days before reaching full 
confluency. 
Similarly, c-kitpos eCSCs isolated from the LV samples were also generally small and 
rounded, with the exception of LV3 which appeared more flattened, generally indicative of a 
more differentiated or precursor-like phenotype (Figure 3.3). The mean time of growth of c-
kitpos eCSCs from the LV samples was 10.9±4.3 days. With the exception of the LV1 sample 
which reached full confluency after 19 days. 
c-kitpos eCSCs isolated from the single RV sample were not as small and rounded as from 
other samples, and appeared more spindle-shaped (Figure 3.3). Cells from the RV1 sample 
reached full confluency in 8 days. 
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Figure 3.1 Phase contrast microscopic images of c-kitpos eCSCs in culture isolated from each 
LA sample, taken at (16.2±2.6) days in vitro. 
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Figure 3.2 Phase contrast microscopic images of c-kitpos eCSCs in culture isolated from each 
RA sample, taken at (15.4±3.6) days in vitro. 
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Figure 3.3 Phase contrast microscopic images of c-kitpos eCSCs in culture isolated from each 
LV sample at (10.9±4.3) days, and RV1 sample, taken at 8 days in vitro. 
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3.3. RNA isolation and purity for human c-kitpos eCSCs isolated from the 4 cardiac 
chambers.  
In order to determine the mRNA expression levels of each c-kitpos eCSCs sample, it was first 
necessary to isolate total RNA of sufficient quantity and quality. Table 3.2 shows the 
concentration and purity ratios for each c-kitpos eCSCs sample from each of the four 
chambers. In terms of RNA quantity, c-kitpos eCSCs isolated from the samples of all 
chambers showed a concentration >200ng/µl, except LA1 which was 40ng/µl (Table 3.2).  
Through utilising the 260/280 and 260/230 ratios, the purity of each sample was determined. 
The 260/280 ratio was consistent with an excellent level of pure RNA (>2), devoid of phenol 
or protein contamination for all samples (Table 3.2).  The 260/230 ratio, which is reflective of 
genomic contamination, was not as consistent, with 5 samples having a 260/230 ratio of <1.7 
(Table 3.2).  
Table 3.2 Nanodrop spectrophotometric analysis for quantity and quality of the RNA 
isolation for c-kitpos eCSCs isolated from each cardiac chamber. (*denotes genomic DNA 
contamination). 
Sample RNA quantity (ng/µl) (260/280) (260/230) 
LA1 40.03 2.01 0.78* 
LA2 270.9 2.05 2.14 
LA3 565.7 2.05 2.18 
LA4 520.7 2.09 0.68* 
LA5 429.5 2.07 2.08 
mean±SD 365.3±213.9 2.05±0.02 1.57±0.77 
RA1 453.2 2.07 1.93 
RA2 508.8 2.08 1.03* 
RA3 448.9 2.07 1.74 
RA4 1345.9 2.1 1.31* 
RA5 789.5 2.08 2.03 
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mean±SD 709.2±382.5 2.08±0.01 1.60±0.42 
LV1 643.7 2.05 1.79 
LV2 248.4 2.08 0.32* 
LV3 881.5 2.07 1.98 
LV4 416.1 2.05 2.15 
mean±SD 547.4±275.4 2.06±0.01 1.56±0.83 
RV1 1042.5 2.08 2.16 
 
3.4. qRT-PCR analysis. 
Following growth, mRNA isolation and PCR technologies key genes of interest can be 
monitored. By plotting fluorescence accumulation against cycle number an amplification plot 
representing the accumulation of product can be generated.  Example plots for all analysed 
genes are presented in Figures 3.4 and 3.5.  Data also reveal the CT value for each gene of 
interest, which is representative of expression levels – higher CTs being indicative of lower 
expression. Having determined the gene expression levels it was important to assess the 
quality of the reaction. From the PCR-derived melting curves it is possible to ascertain that 
genes including: c-kit, Tbx5, Tbx20, Isl-1, Hand-2, FGF-10, HRT-1 and HRT-2 together with 
the house keeping genes GAPDH and beta-actin showed a normal range of melting curves 
and no evidence of primer-dimer formation (Figures 3.6 and 3.7).By contrast, genes 
including: the Foxh-1, FGF-8, Hand-1 and Pitx2 show evidence of abnormal shape of the 
melting curves with evidence of probable mispriming and/or some primer-dimer formations.  
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Figure 3.4 Typical amplification curves of c-kit, Tbx-5, Tbx-20, Pitx-2, Isl-1, Foxh-1, Hand-
1 and Hand-2. Cycle number is shown along the X axis and arbitrary fluorescence units are 
shown on the Y axis. 
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Figure 3.5 Typical amplification curves of for HRT-1, HRT-2, FGF8, FGF10, and 
housekeeping genes β-Actin and GAPDH. Cycle number is shown along the X axis and 
arbitrary fluorescence units are shown on the Y axis. 
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Figure 3.6 Typical melting curves for c-kit, Tbx5, Tbx20, Pitx-2, Isl-1, Foxh-1, Hand-1, and 
Hand-2. The X axis shows the change of the relative fluorescence units with time d (RFU)/d 
T, and the Y axis the Temperature with the peak melting temperature Tm. 
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Figure 3.7 Typical melting curves for HRT-1, HRT-2, FGF8, FGF10, and housekeeping 
genes B-Actin and GAPDH. The X axis shows the change of the relative fluorescence units 
with time d (RFU)/d T, and the Y axis the Temperature with the peak melting temperature 
Tm. 
3.5. c-kit mRNA expression levels of c-kitpos eCSCs isolated from all four cardiac 
chambers.  
All of the samples harvested from the 4 different cardiac chambers were analysed for c-kit 
mRNA expression using qRT-PCR. All samples showed expression of c-kit but at varying 
levels (Figure 3.8). LA, RA, and LV samples were found to express c-kit with a mean relative 
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expression level of (1.52±1.58), (6.04±10.48), and (2.56±4.55) respectively. LA samples 
were the most consistent for c-kit expression, with eCSCs expressing relatively similar 
amounts. The sole RV sample expressed the lowest level of c-kit (0.05).  
 
 
Figure 3.8 qRT-PCR analysis for c-kit expression of c-kitpos eCSCs harvested from the 4 
different cardiac chambers: Bars represent c-kit relative expression levels; error bars 
represent the standard deviation of the mean. (LA: left atria, RA: right atria, LV: left ventricle 
and RV: right ventricle), p value showed no significance difference between chambers. 
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3.6 Transcriptional profile of c-kitpos eCSCs isolated from all the 4 cardiac chambers. 
3.6.1 Left atrium. 
qRT-PCR analysis of the LA samples revealed relative expression of >1 for Tbx5, Tbx20, 
Pitx2, Hand-2, and HRT-2 in all 5 c-kitpos eCSCs samples (Figures 3.9 and 3.10). HRT-1 
showed expression across all 5 c-kitpos eCSCs samples, however this was low being <0.25 
relative expression (Figure 3.10). Hand-1 showed expression, albeit low, in only one sample 
(LA2; ~0.6 relative expression). The other samples were negligible for Hand-1 being <0.05 
relative expression (Figure 3.9).  Isl-1, Foxh-1, FGF-8 and FGF-10 all had no or negligible 
relative expression levels, being <0.08, in all 5 c-kitpos eCSCs samples (Figures 3.9 and 3.10). 
These relative expression levels corresponded with the Ct values (See Table 3.3).  
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Figures 3.9 qRT-PCR analysis of the c-kitpos eCSCs isolated from LA. Bars represent mRNA 
relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate, p=NS.  
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Figures 3.10 qRT-PCR analysis of the c-kitpos eCSCs isolated from LA. Bars represent 
mRNA relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate, p=NS. 
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Table 3.3 Ct values of the LA samples for all the genes of the study (mean±SD). No values 
indicate no expression of the transcripts. 
SAMPLES LA1 LA2 LA3 LA4 LA5 
c-kit 32.55 ±0.94 25.78 ±0.04 30.53 ±0.4 29.29 ±0.31 29.99 ±0.06 
Tbx5 27.21 ±0.13 27.6 ±0.15 27.34 ±0.15 26.3 ±0.22 26.87 ±0.12 
Tbx20 29.05 ±0.57 24.05 ±0.08 24.8 ±0.13 25.11 ±0.32 24.71 ±0.05 
Pitx2 29.57 ±0.33 26.99 ±0.08 30.83 ±0.87 29.7 ±0.29 29.56 ±0.21 
Isl-1 35.79 ±0.81 33.6 ±0.02 
  
34.3 ±0.38 
FoxH1 38.33 32.44 ±0.75 36.47 ±0.22 36.46 36.31 ±0.46 
Hand-1 35.76 ±1.92 28.78 ±0.6 37.12 ±0.86 37.28 ±0.81 36.15 ±1.52 
Hand-2 26.46 ±0.32 28.54 ±0.39 26.1   ±0.3 25.94 ±0.06 25.96 ±0.36 
HRT-1 34.93 ±0.42 31.49 ±0.74 32.62 ±0.33 33.97 ±0.04 33.67 ±0.29 
HRT-2 24.54 ±0.45 24.49 ±0.67 28.29 ±0.1 29.45 ±1.27 28.52 ±0.4 
FGF-8 37.67 35.85 ±1.87 36.83 ±1.99 36.02 
 
FGF-10 
     
β-Actin 22.46 ±0.35 16.02 ±0.08 18.08 ±0.12 17.99 ±0.48 18.18 ±0.08 
GAPDH 19.79 ±0.06 17.03 ±0.6 17.13 ±0.01 17.69 ±0.45 17.45  ±0.05 
 
3.6.2 Right atrium. 
qRT-PCR analysis of the RA samples revealed relative expression of >1 for Tbx20, Hand-2, 
and HRT-2 in all 5 c-kitpos eCSCs samples (Figures 3.11 and 3.12).  3 c-kitpos eCSCs samples 
(RA2, 3 and 4) showed a relative expression level of >1 for Tbx5, however the other 2 
samples (RA1 and 5), showed negligible or no relative expression (Figure 3.11). Similarly for 
Pitx2, RA4 had a relative expression of ~3; however the other c-kitpos eCSCs RA samples 
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were all ≤1 (Figure 3.11). Hand-1 relative expression was <0.25 for all 5 c-kitpos eCSCs 
samples. HRT-1 showed relative expression >1 for RA1, ~0.6 for RA5, yet <0.2 for RA2, 3 
and 4 (Figure 3.12). Similar to LA, Isl-1, Foxh-1, FGF-8 and FGF-10 all had no or negligible 
relative expression levels, being <0.05, in all 5 c-kitpos eCSCs samples (Figures 3.11 and 
3.12).  These relative expression levels corresponded with the Ct values (see Table 3.4). 
 
Figures 3.11 qRT-PCR analysis of the c-kitpos eCSCs isolated from RA. Bars represent 
mRNA relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate, with p=NS.  
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Figures 3.12 qRT-PCR analysis of the c-kitpos eCSCs isolated from RA. Bars represent 
mRNA relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate, with p=NS.  
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Table 3.4 Ct values of the RA samples for all the genes of the study (mean±SD).No values 
indicate no expression of the transcripts. 
SAMPLES RA1 RA2 RA3 RA4 RA5 
c-kit 25.25 ±0.55 31.52 ±0.54 30.34 ±0.19 32.12 ±0.66 26.55 ±0.42 
Tbx5 33.07 ±0.31 27.07 ±0.05 28.08 ±0.11 27.18 ±0.05 35.89 ±0.04 
Tbx20 27.15 ±0.02 23.2 ±0.18 24.5 ±0.11 24.66 ±0.28 25 ±0.08 
Pitx2 34.98 ±1.42 30.42 ±0.19 29.17 ±0.19 28.15 ±0.27 30.2 ±0.3 
Isl-1 35.92 37.84 ±0.58 36.89 35.99 
 
FoxH1 34.7 ±0.22 35.46 ±1.41 36.56 ±1.12 36.03 ±0.8 36.46 ±0.98 
Hand-1 32.36 ±0.15 32.72 ±0.31 33.86 ±0.58 32.71 ±0.54 32.62 ±0.35 
Hand-2 25.75 ±0.44 23.31 ±0.24 25.12 ±0.27 24.18 ±0.08 25.38 ±0.09 
HRT-1 29.88 ±0.66 31.85 ±0.48 32.36 ±0.33 32.35 ±0.07 29.79 ±0.37 
HRT-2 25.88 ±0.09 26.04 ±0.09 26.82 ±0.16 26.5 ±0.18 24.88 ±0.12 
FGF-8 
  
36.61 ±0.17 37.12 ±0.7 
 
FGF-10 37.98 
    
β-Actin 18.14 ±0.35 15.95 ±0.1 17.08 ±0.09 17.82 ±0.16 17.08 ±0.33 
GAPDH 18.05  ±0.3 16.33  ±0.35 17.72 ±0.05 17.34  ±0.24 17.09  ±0.26 
 
3.6.3   Left ventricle. 
qRT-PCR analysis of the LV samples revealed relative expression of >1 for Tbx20, Hand-2, 
and HRT-2 in all 4 c-kitpos eCSCs samples (Figures 3.13 and 3.14).  1 c-kitpos eCSCs LV 
sample (LV2) showed a relative expression level of >1 for Tbx5, however the other 3 
samples (LV1, 3 and 4), showed a lower relative expression of <0.7 (Figure 3.13). Pitx2 had 
a low expression level of <0.4 across all 4 c-kitpos eCSCs LV samples (Figure 3.13). Hand-1 
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relative expression was <0.25 for all 4 c-kitpos eCSCs LV samples. HRT-1 relative expression 
was <0.15 for all 4 c-kitpos eCSCs LV samples (Figure 3.14). Similar to LA and RA, Isl-1, 
Foxh-1, FGF-8 and FGF-10 all had no or negligible relative expression levels, being <0.08, 
in all 4 c-kitpos eCSCs LV samples (Figures 3.13 and 3.14). These relative expression levels 
corresponded with the Ct values (see Table 3.5). 
 
Figures 3.13 qRT-PCR analysis of the c-kitpos eCSCs isolated from LV. Bars represents 
mRNA relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate, with p=NS.  
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Figures 3.14 qRT-PCR analysis of the c-kitpos eCSCs isolated from LV. Bars represents 
mRNA relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate, with p =NS.  
3.6.4   Right ventricle 
After harvesting and isolating 5 RV samples, only the RV1 sample successfully yielded cells 
which could be grown in culture and fully analysed. This sample revealed relative expression 
of >1 for Tbx5, Tbx20, Hand-2, and HRT-2 (Figures 3.15 and 3.16).  Pitx2 had a low 
expression level of <0.4 (Figure 3.15). Hand-1 relative expression was <0.15 (Figure 3.15). 
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HRT-1 relative expression was negligible being <0.07 (Figure 3.15). Similar to LA, RA and 
LV, Isl-1, Foxh-1, FGF-8 and FGF-10 all had no or negligible relative expression levels, 
being <0.05, in all 4 c-kitpos eCSCs LV samples (Figure 3.15 and 3.16). These relative 
expression levels corresponded with the Ct values (see Table 3.5). 
 
Figures 3.15 qRT-PCR analysis of the c-kitpos eCSCs isolated from RV. Bars represent 
mRNA relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate with p=NS. 
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Figures 3.16 qRT-PCR analysis of the c-kitpos eCSCs isolated from RV. Bars represent 
mRNA relative expression levels; error bars represent the standard deviation of the mean. All 
samples were carried out in triplicate with p=NS.  
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Table 3.5 Ct values of the LV and the RV samples for all the genes of the study 
(mean±SD).No values indicate no expression of the transcripts. 
SAMPLES LV1 LV2 LV3 LV4 RV1 
c-kit 25.58 ±0.19 32.37 ±0.59 36.41 ±1.03 31.15 ±0.04 34.37 ±0.95 
Tbx5 30.54 ±0.07 29.74 ±0.12 32.01 ±0.23 31.14 ±0.26 26.64 ±0.07 
Tbx20 25.08 ±0.27 25.77 ±0.04 23.97 ±0.05 27.55 ±0.28 23.72 ±0.05 
Pitx2 31.88 ±1.37 32.49 ±0.23 35.85 ±1.26 31.74 ±0.09 31.32 ±0.32 
Isl-1 36.45 
   
36 
FoxH1 
 
36.27 ±0.81 34.99 ±1.75 36.91 ±0.45 34.53 ±0.22 
Hand-1 36.11 ±1.54 35.03 ±0.06 33.29 ±0.43 33.78 ±1.36 33.26 ±0.51 
Hand-2 26.85 ±0.42 27.31 ±0.03 24.75 ±0.32 27.38 ±0.26 24.76 ±0.12 
HRT-1 31.97 ±0.14 34.7 ±0.28 32.8 ±0.18 35.98 ±0.05 33.94 ±0.19 
HRT-2 29.86 ±0.48 28.64 ±0.15 25.65 ±0.16 32.21 ±0.28 29.14 ±0.15 
FGF-8 38.51 37.8 ±0.65 
   
FGF-10 38.49 
 
37.5 ±0.16 35.51 ±0.55 
 
β-Actin 17.08 ±0.11 18.37 ±0.21 17.64 ±0.17 18.44  ±0.66 17.85 ±0.17 
GAPDH 18.04 ±0.32 17.99 ±0.09 17.48 ±0.16 18.38 ±0.18 17.42 ±0.19 
 
3.7 Cumulative qRT-PCR analysis between all 4 cardiac chambers. 
In order to compare the expression of our genes of interest across the four cardiac chambers, 
the individual sample data described above were cumulated (Figures. 3.17 and 3.18). qRT-
PCR analyses across LA, RA and LV cardiac chambers revealed a significant (p<0.05) 
increased relative expression of Tbx5 in the LA, compared to LV (Figure 3.17). There were 
no significant differences in relative expression between chambers for the other transcripts 
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(Figures 3.17 and 3.18). Data reveals that TBX20, TBX5, HAND2 and HRT2 show elevated 
relative expression levels, whereas the relative level of expression of all others is low.  When 
compared to basal Ct values of these genes TBX20, TBX5, HAND2 and HRT2 with all the 
other genes, it is obvious that they have the lowest Ct values which confirm their higher 
expression during qPCR (see Table 3.6). 
Figure 3.17 cumulative qRT-PCR analyses for all 4 cardiac chambers. Bars represent mRNA 
relative expression levels; error bars represent the standard deviation of the mean. n=5, 5, 4 
and 1 for LA, RA, LV and RV, respectively.*p<0.05 vs. LV. 
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Figure 3.18 cumulative qRT-PCR analyses for all 4 cardiac chambers. Bars represent mRNA 
relative expression levels; error bars represent the standard deviation of the mean. n=5, 5, 4 
and 1 for LA, RA, LV and RV, respectively with p=NS.  
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Table 3.6.Ct values of the most expressed genes TBX5, TBX20, HRT2 and HAND2 from all 
the cardiac chambers. 
 
LA Tbx5 27.21±0.13 27.6 ±0.15 27.34 ±0.15 26.3 ±0.22 26.87 ±0.12 
 Tbx20 29.05 ±0.57 24.05 ±0.08 24.8 ±0.13 25.11±0.32 24.71 ±0.05 
 Hand-2 26.46 ±0.32 28.54 ±0.39 26.1   ±0.3 25.94±0.06 25.96 ±0.36 
 HRT-2 24.54 ±0.45 24.49 ±0.67 28.29 ±0.1 29.45±1.27 28.52 ±0.4 
RA Tbx5 33.07 ±0.31 27.07 ±0.05 28.08 ±0.11 27.18±0.05 35.89 ±0.04 
 Tbx20 27.15 ±0.02 23.2 ±0.18 24.5 ±0.11 24.66±0.28 25 ±0.08 
 Hand-2 25.75 ±0.44 23.31 ±0.24 25.12 ±0.27 24.18±0.08 25.38 ±0.09 
 HRT-2 25.88 ±0.09 26.04 ±0.09 26.82 ±0.16 26.5 ±0.18 24.88 ±0.12 
LV/RV Tbx5 30.54 ±0.07 29.74 ±0.12 32.01 ±0.23 31.14±0.26 26.64 ±0.07 
 Tbx20 25.08 ±0.27 25.77 ±0.04 23.97 ±0.05 27.55±0.28 23.72 ±0.05 
 Hand-2 26.85 ±0.42 27.31 ±0.03 24.75 ±0.32 27.38±0.26 24.76 ±0.12 
 HRT-2 29.86 ±0.48 28.64 ±0.15 25.65 ±0.16 32.21±0.28 29.14 ±0.15 
 
3.8 Statistical analysis results of the data. 
Due to the vast variability of the samples from different chambers and from different  patients 
with a number of  co-factors and as the number of genes was analysed from  each chamber  a 
complex statistical analysis was performed in order to avoid errors. Firstly the data has been 
analysed for multiple testing and this proved to be that the data had no linearity.Secondarly 
using the Shapiro-Wilk test to look for normalisation of the data we calculated the 
significance value of each gene which needed to be greater than 0.05.We find out that most of 
the genes were normaly distributed except two the Hand -1 and HRT-1 gene (see table 3.7 
below). Finally when we look for significant differences using the ANOVA with Tukey post 
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hoc tests and setting the significance at p<0.05 we identified only  in the TBX-5 gene (as it is 
been shown in figure 3.17) after cumulative qRT-PCR analyses for all 4 cardiac 
chambers,there was significance difference between the RV,RA,LA  versus the LV chamber 
with a p value of less than 0.05 (p<0.05) .In all the other analysis of the genes during PCR  
the data didn’t showed any statistical significance between the genes from all the samples 
taken from the 4 cardiac chambers. 
Tests of Normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
Tbx5 .200 7 .200* .939 7 .631 
Pitx2 .146 7 .200* .968 7 .886 
Tbx20 .164 7 .200* .958 7 .803 
Isl-1 .261 7 .161 .838 7 .096 
FoxH1 .324 7 .026 .822 7 .067 
Hand-1 .376 7 .003 .655 7 .001 
Hand-2 .250 7 .200* .930 7 .554 
HRT-1 .417 7 .001 .561 7 .000 
HRT-2 .303 7 .051 .813 7 .055 
FGF-8 .267 7 .140 .903 7 .352 
 
Table 3.7. Tests of normality of the distribution of the data.Please note that the data in green 
are nortmally distributed with a value of  greater than 0.05 and the data in red are not with 
values more than 0.05. 
 
 
 
 
 
 
74 
 
Key Points 
 The number of c-kitpos eCSCs and number of c-kitpos eCSCs per gram of tissue 
isolated from all the 4 human cardiac chambers seems to be consistent, with minor 
variances (not statistical significant) accordingly to the weight and size of the 
samples. 
 Transmitted light microscopic observations of c-kitpos eCSCs in culture from all the 
four cardiac chambers revealed that most of the isolated c-kitpos cells from the human 
biopsies were generally small and rounded, consistent with a stable c-kitpos eCSCs 
phenotype despite the chamber of origin.  
 eCSCs c-kitpos can grow in cell culture in hypoxic conditions (2-5% O2) between 
7±5.5 days where they reach full confluency. 
 All samples showed expression of the stem cell factor receptor c-kit but at varying 
levels. LA samples were the most consistent for c-kit expression, with eCSCs 
expressing relatively similar amounts of this gene. 
 Transcriptional analysis using qRT-PCR revealed that all the 4 cardiac chambers host 
c-kitpos eCSCs which express genes from the primary and secondary heart field with 
variances.Cells expressing much more consistenly genes from the secondary heart 
field like TBX-5,TBX-20,HAND-2,HRT-2 and  minor expression of the PITX-2 gene 
again from the secondary heart field. 
 Minimal or no expression was revealed for Hrt-1, Isl-1, Foxh1, Fgf-8 and Fgf-10 in 
all 4 chambers. This has been confirmed with the higher or absent Ct values of these 
genes. 
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4. DISCUSSION 
The key objectives of this study were primarily to isolate c-kitpos eCSCs from all the four 
cardiac chambers and compare their numbers isolated between chambers. A secondary 
objective was to investigate, using qRT-PCR whether these c-kitpos eCSCs isolated from the 
four chambers of the human myocardium, could express uniformly all the genes of the 
primary and secondary heart fields.  
It was hypothesized that c-kitpos eCSCs would be obtained with greater ease from the right 
and left atria, and fewer number of eCSCs would be obtained from the left ventricle and right 
ventricle respectively. It was further hypothesized that the eCSCs when isolated from the  
four  different cardiac chambers and analyzed by qRT-PCR for their transcriptional profile of 
genes specific to the primary and secondary heart field and chamber of origin, they could 
have the same genetic profile and could be ‘’generic’’ and  not ‘’chamber specific’’. 
The major finding of this study was that the eCSCs isolated from the 4 chambers of the 
human myocardium are c-kitpos and they reside in all the cardiac chambers RA, LA, LV and 
RV with no significant differences between these chambers. When qRT-PCR used to 
investigate their transcriptional profile, revealed that they express genes from both the 
primary and secondary heart fields, suggesting they are not chamber specific but generic 
regardless of their location of origin. 
4.1 The number of eCSCs isolated varied across the cardiac chambers. 
All the samples harvested from the 4 cardiac chambers showed variability in their weight and 
number of eCSCs per gram of tissue after enzymatic isolation and MACS procedure.This was 
an inevitable variable which was introduced by the discretion of the surgeon who was 
harvesting the sample and from the operator who was isolating the eCSCs in the laboratory. 
Sometimes despite asking for the biggest sample in order to achieve more cells at the end of 
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the enzymatic digestion [an optimal size between 5mgr-1gr as has been recorded by our 
group (106) and by others from previous studies (105,128,136,153), due to safety to avoid 
bleeding a small size samples were given for analysis by the surgeon who was performing the 
operation. So when the samples were arriving in the laboratory in order to proceed with the 
enzymatic digestion and finally MACS procedure, a number of times the expected amounts 
of cells that were isolated in comparison to the weight of the samples were not satisfactory. 
Because of these limitations and in order to achieve consistent and meaningful results, more 
than 30 samples were processed and eCSCs processed to isolation by the same operator to 
ensure a level of consistency and optimization of the learning curve. The trial and error 
period, was enough to achieve sufficient practice of the procedures of isolation and optimize 
the protocols in order to isolate and process safely the samples. From all these 30 cardiac 
biopsies only 15 samples were analyzed to completion from all the 4 human cardiac 
chambers and the results have been recorded and analyzed for this thesis. 
Some  samples were small in weight but had a good amount of cells isolated per gram of 
tissue (see for example in Table 3.1  that LV1 sample with a weight of 0.025gr and a number 
of c-kitpos cells per gram of tissue of 120000; similarly LV3 sample  with weight of  0.068gr  
and number  of c-kitpos cells per gram of tissue of  52941 and RV1 sample with 0.033gr and 
number of c-kitpos cells per gram of tissue of 75000); Most of these samples were more 
muscular in comparison of the LA and RA samples as they have been harvested from the 
endocardial layers of the LV and RV during mitral or tricuspid valve repair/replacements 
respectively. Some had a higher weight but after enzymatic digestion of the tissue and MACS 
procedure no cells were isolated (data not shown as not cells isolated so the samples have 
been discarded and not been included in the data of the analysis of this thesis). 
Finally some were big in size with a good yield of cells per gram of tissue after isolation as 
for example the LV2 sample with 0.243gr of sample weight and 39506 c-kitpos cells per gram 
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of tissue; in contrary with the RA1 sample who had 1gr of weight but only 6400 of c-kitpos 
cells per gram of tissue. The difference in the variability of the weight could be attributed to 
the presence of epicardial fat and fibrous tissues depending of the area of harvesting; samples 
harvested from the RA appendix had more epicardial fat in comparison of the other samples 
from the other cardiac chambers. LA samples had more fibrous tissues in comparison of the 
LV or RV samples. The ventricular samples as they were harvested from the endocardial 
layers of the LV and RV chambers, they were more muscular with less fat but less volume in 
size. Based on our previous experience protocols of harvesting and processing human cardiac 
samples (106) and with the Smitts protocol publication (108) who tried to give an insight of 
the in vitro model of the cardiomyocyte progenitor cells and standardize their methods of 
differentiation in vitro, the above variability of the harvested samples and process during 
enzymatic isolation deemed to be acceptable according the methodology and aims of this 
study.    
In addition there is no evidence yet of how the Cardio Pulmonary Bypass (CPB) can affect 
the samples and in consequence the number of the eCSCs in response to the CPB 
inflammation-induced process. All the samples from RA were harvested before initiation of 
Cardio-pulmonary Bypass and were 2-3cm in size as shown in Figure 2.1 in the methods 
section; the same techniques of harvesting were reported (128) in the SCIPIO trial. It was 
reported that harvesting myocardial samples from the right atrial tissues was easier, 
especially for the RA appendix as it provided the safest access during venous cannulation of 
the RA/IVC, prior to initiation of cardiopulmonary bypass. The LA samples instead were 
harvested after the initiation of the CPB and cross clamp of the aorta with cooling the heart to 
34 ºC. As the LA is the most posterior chamber of the heart and its appendix is in an 
awkward anatomical position, with the potential to bleed all these five  LA  samples 
harvested for this study were taken from the inside of the LA during mitral valve procedures 
78 
 
when access is viable from the Waterstones groove (154). The LA samples harvested in the 
human study by Arsalan (105) used similar methodology.  
Similarly the LV and RV samples were obtained after initiation of the CPB and cross clamp 
the aorta with temperature of 34 ºC in order to have a stable and safe area of harvested tissue. 
Three out of 4 samples were harvested from the inside of the LV in the area of the muscular 
septum below the aortic valve during aortic valve procedures and/or aortic valve root 
procedures. Only one sample which was the smallest one in size was harvested from the 
outside of the deep epicardial layer of the LV and no samples were harvested from the LV 
apex in this study as other studies recorded in the literature (106,107). From the five samples 
that were harvested from the RV throughout the period of the study only one was fully 
processed and analyzed as the other RV samples after enzymatic isolation yielded no cells 
after the MACS procedure. Due to the difficulty of harvesting samples from the ventricular 
epicardial layer of the RV wall with risk of bleeding -especially with patients with pulmonary 
hypertension- surgeons were reluctant to harvest these samples from the outside epicardial 
RV layer. 
To our knowledge except of our study (in humans) there are only three other studies in which 
human samples were tempted and harvested as surgical biopsies from the RV. One study by 
Itzhaki-Alfia (137) obtained RV samples in order to identify c-kitpos cells and correlate their 
number to the original pathology in living patients. Another study by Castaldo (138) the RV 
samples were obtained from normal adult hearts derived from patients who had died for 
reasons other than cardiovascular disease in order to identify positivity for CD117 and to 
assess whether it localized in the sub-epicardium and whether their activation was associated 
with Laminin-1 and a6 Integrin expression. Recently a study performed by Matuszczak (155) 
has analyzed the distribution of the c-kitpos eCSCs from myocardial tissues biopsied from all 
the cardiac chambers including the RV from explanted hearts obtained from recipients during 
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cardiac transplantation. It is been found after FACS analysis that there is equal distribution of 
eCSCs c-kitpos thorough the heart including the RV chamber.  
It is of interest to notify that in this study all these samples were from adult patients who were 
suffering from ischemic cardiac disease (3VD, 4VD) amenable to coronary artery bypass 
grafting (CABG) or a valve pathology (mitral aortic or tricuspid stenosis or regurgitation) 
amenable to surgical repair or replacement of these valves. As we can see on the Table 3.1 
the mean age of all the patients were about 75 years old with prevalence of males in 
comparison to females and with not any significant difference of age between patients from 
the different harvested samples  from different cardiac chambers: (75.2±5 for LA samples, 
76±14 for RA samples and 73.5±8 for LV samples with 74 on the RA sample patient 
group).This can be in accordance with the recent report of Ellison (156) where the age is not 
a limiting factor of the presence or absence of the eCSCs, however in accordance with the 
study of Tallini (157) fetal and young mammalian  hearts they have a better number of eCSCs 
as Matuszczak confirmed from human  pediatric cardiac biopsies who underwent 
transplantation (155). The number of cells could be important when the regeneration process 
is triggered but the quality of the cells and their response to the physiological cardiac 
adaptation to the stress is definetly crucial. The combination of cardiomyocyte hypertrophy 
and hyperplasia (cardiomyocytes and capillaries) plays an important role on the viability of 
these cells during the process of re-adaptation after exercise stress (158). On the other hand 
all these patients were on simvastatin treatment and several studies suggested that (3-
hydroxy-3-methylglutaryl coenzyme A) HMG-CoA reductase inhibitors benefit the patient 
with an ischemic and non-ischemic cardiomyopathy (159). This mechanism has been poorly 
understood if the statins protect against myocyte hypertrophy and cell death together with the 
stimulation of new myocytes from the eCSCs pool. As mentioned earlier despite been adult 
patients with cardiac pathologies the number of the eCSCs was not different between the 
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patients but the quality of these cells who could depend on the endogenous growth factors/ 
statins could give to the cells a better response and adaptation to stress despite the less 
number in comparison of the pediatric samples as has been recorded (155). 
4.2. Morphologically all the eCSCs showed similar pattern of growth in culture. 
Transmitted light microscopic observations of c-kitpos eCSCs in culture revealed that most of 
the isolated c-kitpos cells were generally small and rounded, consistent with a c-kitpos eCSC 
phenotype (106). The eCSCs were cultured in hypoxic conditions for 14±7 days and after 
reaching full confluency they were tripsinized and stored to -80 ºC for further RNA analysis. 
This techniques of culture has been adopted from our previous work in our laboratory that 
have been optimised based on the same protocols that other researchers have reported (111), 
(108). All cells, isolated from each chamber, had a similar morphological aspect in culture. 
The phenotypes of the sample cells were consistent with the c-kitpos eCSCs, reported in our 
previous studies (106). Interestingly, the single RV sample showed very rapid progress in 
culture. The c-kitpos eCSCs were not as small and rounded as other samples, appearing more 
spindle-shaped and reaching confluency in 8 days.  
These morphological and growth differences may be due to a number of factors that affect 
cell growth in culture, including the age of patients, comorbidities, gender and underlying 
pathology (137).  Pouly (160) recorded that the location of the harvested samples can be a 
factor on the type of eCSCs and Parker (161) argued that the time in culture can underpin 
alterations in the phenotype of cells. The age and pathology of the patients could play a role 
in the quantity and quality of the cells but although the cloning efficiency was inversely age-
related, single-cell derived eCSC clones obtained from young and old hearts were 
indistinguishable by their gene expression and differentiation potential, strongly suggesting 
that eCSC aging is a stochastic process as has been recorded from a recent study done by 
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Ellison (156). Interestingly, while failing hearts have increased numbers of c-kitpos 
progenitors, age has been correlated with a decrease in the number of functional progenitors. 
Disease and gender affect the distribution of cells; females tend to have a greater number of 
c-kitpos cardiac progenitors (137). Medical history, including the use of β-blockers, statins, 
smoking, atrial fibrillation, and prior myocardial infarction, can also influence the frequency 
of c-kitpos progenitors in the heart (162).  Failing hearts have an approximate fourfold 
increase in c-kitpos progenitor cells, and it has been shown that approximately 80% of these 
cells co-express CD45 which are mast cells (163). All patients recruited to this project were 
sick patients who underwent open heart surgery and suffered of ischemic cardiomyopathy, 
aortic or mitral valve disease and tricuspid valve pathology. As previously mentioned, 
techniques and patient related characteristics may play a significant role in the growth and 
progress of the cells in culture. However, in this study the morphology and average number 
of cultured eCSCs was generally consistent. 
4.3 m-RNA purity & c-DNA synthesis.  
In our study samples harvested from all the chambers showed a normal ratio level of the 
260/280 which showed good level of DNA purity of the samples with the mean value for the 
LA chambers of 2.05±0.02, for the RA chambers of 2.08±0.01, for the LV of 2.06±0.01 and 
for the unique RV of 2.08 respectively. This confirms good operator technique and purity of 
the samples. However there were samples as LA1, LA4, RA2, RA4, LV2 that had low 
260/230 ratio and this could suggest presence of contaminants or low RNA content as the 
samples were small in size. As mentioned earlier in previous paragraphs, the learning curve 
of these specialist and delicate techniques of the operator might have a contribution on these 
m-RNA purity results in additional of the small samples sizes who some of them had low 
number of c-kitpos eCSCs; (see Table 3.1 and Table 3.2 in the Results Section). It is obvious 
that LA1 sample has a low weight 0.123gr with an RNA quantity of 40.03ng/µl, where the 
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sample LA4 had been low weight 0.086gr with an RNA quantity of 520.7ng/µl but with a 
low ratio of 260/230 suggesting genomic contamination and operator technique. Similarly 
with RA2, RA4, LV2 despite a weight of 0.277g, 0.227g, and 0.243g respectively the 
260/230 ratio of 1.03,1.31 and 0.32 respectively, suggesting poor operator technique.   
 4.4 qRT-PCR and c-kit expression. 
As has been recorded in the results section c-kitpos eCSCs were distributed throughout the 4 
cardiac chambers between LA, RA, LV, and RV. All of the samples showed expression of c-
kit but at varying levels LA, RA, and LV samples were found to express c-kit with a mean 
relative expression level of (1.52±1.58), (6.04±10.48), and (2.56±4.55) respectively. LA 
samples were the most consistent for c-kit expression, with eCSCs expressing relatively 
similar amounts across samples. The RA samples showed variability in their ckitpos eCSCs, 
and three of the four LV samples showed good amount of c-kitpos expression. The sole RV 
sample expressed the lowest level of c-kit (0.05).When examining closely the number of c-
kitpos eCSCs distributed at the 4 cardiac chambers (see Table 3.1 at the results section) there 
were differences of c-kitpos accordingly to the different anatomical locations with distribution 
in the LA with mean±SD of 34601±11720, for the RA 15076±11470 and for the LV 
49945±42097 respectively. The sole sample of the RV had 75000 cells per gram of tissue. 
These numbers are  in accordance with previous studies of our group were the amount of 
cells  were about 25000 to 50000 cells per gram of tissue using the same techniques of 
enzymatic isolation (106). 
Regarding the variability of the c-kitpos eCSCs between chambers this study agreed with the 
studies of Arsalan (105) regarding the superiority of the LA to contain a higher amount of 
eCSCs c-kitpos cells per gr of tissue in comparison with the other cardiac chambers. Arsalan 
used the same harvesting techniques and similar enzymatic isolation of the eCSCs however 
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he analyzed the c-kitpos expression using FACS analysis not qRT-PCR. The presence or not 
of the c-kitpos cells  can be confirmed or excluded with either analytical technique but  
because the purpose of our study was to look for c-kitpos gene expression of the eCSCs of the 
primary and secondary heart fields, the qRT–PCR was primarily used in order to  have 
meaningful and accurate results for each gene expression. In addition Arsalan has not studied 
the RV but reached conclusions with RA, LA and LV samples only. 
Recent studies (155) analyzed the distribution of the c-kitpos eCSCs from the myocardial 
tissues and in cell cultures derived from explanted hearts obtained from recipients during 
transplantation. It has been found equal distribution of eCSCs c-kitpos throughout the 
myocardial chambers and the RV, while FACS analysis was performed. In our study we 
tempted to analyze RV samples also, despite the fact that only one sample -of the 5 RVs that 
were processed- has been fully and completely analyzed. The patient that this sample has 
been harvested was a 74 years old male who suffered of mitral valve stenosis and tricuspid 
valve regurgitation. He was generally fit and well with cycling of weekly basis 10km all his 
life. As he recently had more shortness of breath due to his progressing pathology he 
underwent an echocardiographic imaging that relieved the diagnosis. It could be speculated 
as reported in the literature (156) that despite of this patient age and because of his fitness and 
general health status his myocardial mass was well refurnished of eCSCs who were 
distributed in his RV in order to encourage reverse remodeling and regeneration despite his 
underlying valve pathology (158).   
In the two studies where RV samples were harvested from living and cadaveric samples 
(137,138), the presence of eCSCs were c-kitpos confirmed, but their number were minimal in 
comparison to the other cardiac chambers. Our results (albeit of  only one sample) agreed 
with these findings as fewer eCSCs were isolated from the RV and of 5 samples harvested, 
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only one yielded able to be cultured cells, suggesting that eCSCs may be reduced in number 
in the RV.   
The RA chambers in our study showed variability in the number of the c-kitpos eCSCs but still 
agreed with previous studies (106,128,137), supporting the idea that the RA provides and 
accessible deposit of myocardial progenitors that can be easily mobilized in case of 
myocardial injury in order to maintain myocardial integrity. The right atrium, a region of low 
mechanical stress, with the highest CD117-positive cell and laminin content as supported by 
the study of Castaldo (138), may constitute the privileged site for the primitive cells, which 
survive during pathological conditions involving the ventricles and migrate across the sub-
epicardial space or myocardium to the regions of damage and regeneration. 
Another relevant observation that can affect the number of the c-kitpos cells in the already sick 
hearts of the patients of our study is the inverse relationship between cardiac pathology and 
presence of c-kitpos cells. Most of the patients were sick with abnormal LV ejection function 
and early stage heart failure. Previous reports also correlated increased numbers of CPCs in 
humans with significant aortic stenosis, acute and chronic ischemia, and other 
cardiomyopathies (163,164,165,166). Together, these findings support the notion that the 
endogenous reparative system is stimulated in the injured heart in different level and intensity 
(167). A recent report has suggested that c-kitpos cells have increased proliferative capacity 
when cultured with extracellular matrix obtained from a failing heart (138). Thus, local 
signals that can stimulate eCSCs in response to injury could explain the mobilization of these 
progenitor cells from the rich atria to the damaged ventricles and support myocardial 
regeneration using paracrine messages. 
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4.5 Variable expression of genes from both the cardiac fields from the eCSCs of the four 
cardiac chambers. 
In order to understand better the genetical profile of the eCSCs and their gene expression in 
this study, a correlation with the primary and secondary heart fields has been implemented. A 
heart field it defines as a discrete embryonic region in which cells that have myocardial 
potential are located (168) .The theory of heart fields gives an insight of the process of 
cardiogenesis and a better understanding of the congenital pathologies. The inter-relation 
dynamics of these genes between the heart fields is enormous and poorly understood however 
during cardiac embryogenesis some genes are expressed and some switch off according to the 
time and production of the transcription factors to activate key developmental pathways. 
Hand-1 is the Heart and neural crest derivatives expressed protein 1. In humans is encoded by 
the Hand-1 gene (169,170). The protein encoded by this gene belongs to the basic helix-loop-
helix family of transcription factors (171). The Hand-1 gene expressed form the LV (as 
equally the Nkx-2.5 and TBX-5 genes) is expressed with the myocardium of the primary 
heart field and plays an essential but poorly understood role in cardiac morphogenesis. Hand 
factors function in the formation primarily of the left ventricle, right ventricle, aortic arch 
arteries, epicardium, and endocardium implicating them as mediators of congenital heart 
disease. After analyzing our 15 samples using the qRT-PCR we identified that the Hand-1 
gene is miniamlly expressed in all of the eCSCs from all the chambers with less expression 
on the LV but uniform and very low expression on the RV and better expression on the LA 
samples and RA sample. Despite the Hand-1 been a marker of the Primary Heart Field 
(PHF), when this marker was investigated in the eCSCs in this study it was found in minor 
quantities according to the size and location of the sample in all the cardiac chambers (see 
figure 3.17 in the results section). Unfortunately due to the design of this study we haven’t 
investigated the gene expression of the Hand-1 gene in the cardiac chambers samples before 
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the extraction of the eCSCs for comparison. However in accordance to the study of 
McFadden (172) the cardiac samples when only analyzed for expression of these genes they 
do flag Hand-1 and Hand-2 genes during cardiac embryogenesis in the mouse model. 
The secondary heart field describes a population of cardiac progenitor cells identified in the 
pharyngeal mesoderm that gives rise to a major part of the amniotic heart (173). These 
multipotent progenitor cells, termed the second heart field (SHF), contribute progressively to 
the poles of the elongating heart tube during looping morphogenesis, giving rise to 
myocardium, smooth muscle, and endothelial cells. The secondary heart field divides on its 
anterior part which is programmed to make outflow tract and RV and its posterior part where 
the atrial myocardium it gets formatted. A number of transcripts have been identified who are 
marking the evolution and formation of these cardiac structures. These genes are listed in the 
Table 4.1 below with the cardiac and vascular structures related. 
In our study after analyzing the 15 cardiac samples from all the cardiac chambers the eCSCs 
they express TBX5, TBX20, and HAND-2 & HRT-2 (with low levels of PITX-2) genes 
universally in the myocardium (see figures 3.17 and 3.18 in the results section), which 
suggests the potential of these genes to be still presence in adult heart and support 
differentiation of these potent cells when the myocardium needed in case of myocardial 
ischemic insults and loss of myocardial function. 
Table 4.1.Genes expressed by the Secondary Heart Field and associated structures that are 
involved on their expression. (*Noticed that TBX-5 is not expressed in the SHF but it plays a 
role on suppressing genes of the PHF/SHF during cardiac embryogenesis). 
GENE STRUCTURE 
FGF-8 outflow tract 
FGF-10 aorta &  pulmonary trunk 
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TBX-1 RV, outflow tract 
ISL-1 outflow tract, RV, atria 
FOXH-1 RV 
MEF2C from cardiac crescent to SHF,RV 
HAND-2 RV 
TBX-20 RV, LV 
*TBX-5 LV, atria, inflow tract, in PHF  potentiates LV, in SHF suppress other 
structures  
 
In this study as the TBX genes are typical marker genes for the cardiac mesoderm, all the 
eCSCs isolated form all the cardiac chambers showed persistently good expression of the 
TBX5 and TBX20 genes. All their melting curves from all the samples had optimal Ct values 
and excellent curve morphology (see figure 3.6 and table 3.6 in the results section). The fact 
that these genes showed a very good expression in all the eCSCs form all the chambers 
confirms the importance of these genes on the cardiac chamber formation (174). In the adult 
myocardium the eCSCs who were isolated still retain the memory of these genes in all the 
cardiac chambers. This comes in accordance with the recent studies by Mauritz (175) in 
murine samples, which showed that when iPS cells can differentiate in cardiac myocytes they 
still express the TBX genes together with all the other genes of the mesodermal cardiac 
lineage. 
The importance of the HRT1 and HRT2 genes in the cardiogenesis is crucial and already a 
gene defect can produce a serious malformation as has been reported by the team of 
Srivastava (176). In this study it has been identified that all the eCSCs that have been isolated 
from the 4 cardiac chambers showed consistency of expression only of the HRT2 gene (see 
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figure 3.18 in the results section). This consistency has been confirmed when has been 
correlated to the Ct values of these genes in the melting curves during qRT-PCR recorded in 
the figure 3.7 in the results section.Unlike the HRT-2, the HRT-1 gene didn’t show any 
significance expression thoroughout the 4 cardiac chambers in all the samples taken.We can 
speculate that the HRT-1 gene who belongs on the primary hart field switches off after the 
embryogenesis after the LV chamber is been formatted so the secondary heart field has genes 
who can be still on even in the adult  eCSCs genes. 
Similarly in genes with high embryological importance and multipotency like the ISL-1, in 
this study it was found in minimal or negligible expression and only in the atrial and not in 
the LV or RV chambers. This confirms previous studies of the importance of the atria as 
depositors of progenitor cells instead of the ventricles (149).  The presence of the ISL1 genes 
early in the cardiogenesis and the fact that these genes are expressed not only in the embryo 
but also in the adult (177) and especially with cells of the conductive system (178) suggests 
that the eCSCs that express this gene in our study is a more atrial in nature gene and not a 
ventricular one. Atria have been already identified as the areas of eCSCs deposits from 
previous studies of Kajstura (179) and as has been mentioned earlier in the work of Castaldo 
(138) these deposits of the eCSCs can be mobilized to the areas needed when a myocardial 
injury happens. It seems that these deposits of the eCSCs found in our study which only 
express ISL1 in the atria can confirm the above hypothesis of the group of Castaldo. 
Genes as the Pitx2 member of the RIEG/PITX homeobox family, recently in the studies of 
Kirchhof (180) showed the importance of this gene which demonstrate that PITX2c is 
expressed in the adult human and mouse left atrium and that reduced expression of this 
isoform in mice causes shortening of atrial action potential duration and susceptibility to 
induced AF. In our study this gene was expressed minimally in eCSCs isolated throughout 
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the myocardial chambers but with better expression in the LA and even less expression to the 
other chambers (see figure 3.17 in the results section). 
The Foxh1 is a forkhead-DNA binding transcription factor in the TGF-β Smad pathway. In 
our study the expression of this gene, which belongs to the secondary anterior heart field, was 
most of the samples from all the cardiac chambers, in minor concentrations (see figure 3.17 
in the results section). Identification of this gene in the adult cardiac samples of the eCSCs 
shows how these cells can still retain a memory of the cardiac embryogenesis.  
Genes of the fibroblast growth family as FGF8, FGF10, have been minimally or not 
expressed in our study; (see figures 3.17 and 3.18 in the results section). FGF-8 gene was 
minimal in LA RA, LV and no expression at all was evident in the RV. It appears that the RV 
does not retain expression these genes in the eCSC progenitors and this is probably due to the 
dynamics of the gene expression and down regulation during the cardiac embryogenesis of 
the secondary heart field (180). The Ct values of the above findings correlate well with the 
expression or minimal expression of this gene in the qRT PCR results in these studies (see 
tables 3.3-3.6 in the results section). Similarly the FGF-10 gene in our study showed minimal 
expression in RA and LV (see figures 3.12 & 3.14 in the results section) and no expression at 
all in LA and RV. Previous studies by Itzaki-Alfia (137) supported that the RA is the richest 
chamber of endogenous progenitors and as such the RA in this study confirms minimal but 
some expression of this gene. The fact that we couldn’t identify expression in the other 
chambers could be explained simply by the fact that the eCSCs have no expression or that the 
primers have failed, although the latter is unlikely given the stringent primer design protocol. 
Another explanation of the absence or minimal expression of these important mesoderm 
genes could be that during completion of the cardiac embryogenesis they quit their 
expression as other more powerful genes as TBX and HAND family genes keep suppress 
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their expression in order to keep the identity of the chamber of origin but have a memory to 
the other chambers in endogenous progenitor cells as the eCSCs and reactivate them in case 
the myocardium needs them. The age of the patient could be another reason of these eCSCs 
not to express the above genes. We can speculate that Wnt/β-catenin signaling playing an 
upstream role in promoting proliferation of the SHF in vivo, in addition to promoting 
expansion and maintaining multipotency of ISL-1 positive ESC derived cardiac progenitor 
cells (182,183). Furthermore studies by Ellison (156) provide evidence for a role of the 
Wnt/β-catenin and Bmi-1 pathways on eCSC senescence. When eCSCs isolated from old 
hearts were grown in Wnt3A conditioned media or transfected with a lentivirus driving Bmi-
1 expression, the aged/senescent impairment in proliferation was corrected. 
When considering these facts it appears that the original hypothesis for this study has been 
proven where the eCSCs express most of the genes from the primary and secondary heart 
field with half of them expressed in a relevant level and a number of them in minor or 
negligible quantities in the adult human myocardium. With this result they showed a global 
and generic genetical profile throughout the myocardium despite minor variances and non-
expression of some genes from the SHF which probably suggests that these genes are not 
presented (or switched off by other genes), in the adult myocardial eCSCs.  
5. CLINICAL RELEVANCE OF THE STUDY 
In this thesis it was hypothesized that eCSCs isolated from the 4 chambers of the human heart 
would have a universal transcriptional profile rather than a profile that reflects their chamber 
of origin. This would give the added advantage of being able to isolate c-kitpos eCSCs from 
any of the four cardiac chambers to produce cardiomyocytes that exhibit specific 
characteristics of the chamber that they are required to regenerate. This will increase their 
viability for future cell therapy in patients with cardiac failure.  
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In order to replace the damaged myocardium without compromising the local cardiac milleau 
and create any kind of disturbances like arrhytmias, regional wall abnormalities, or any 
regional non viability and fibrosis the cells that needed to be supplied or stimulated via 
growth factors needed to be the same in their genetical and functional characterictics.  
In order to do so as this thesis suggested and confirmed other previous studies, harvesting the 
eCSCs from the right atrial chamber is the most easy and less harmfull way. Genes expressed 
from the atria are more likely to be the same form all the other chambers with minor 
variances. Cells can be easily produced in a cardiac stem cell laboratory and used afterwards 
to be introduced in the human damaged myocardium or together with growth factors in order 
to trigger regeneration. This will give better myocardial contractility and clinical 
improvement of the patients exercise tolerance with better quality of life. 
6. LIMITATIONS OF THE STUDY 
Every study in basic science research has limitations which can be attributed to the design of 
the study its material and methods and its analysis of the results. In this study we appreciate 
that some limitations exist. 
Firstly the operator of this project is a senior trainee in heart surgery with major interest in 
cardiovascular research and translation medicine and as such it was his first time to work and 
get used on basic science laboratory procedures, so a learning curve time has been passed 
before he achieved optimal handling in the instruments and be familiar with the laboratory 
techniques of the micro-cosmos of the cardiac stem cell biology. For that reason more than 30 
samples were analyzed and only 15 were finally achieved complete results in order to 
successfully complete this project. Some samples despite using the same technique of 
harvesting and analysis they have not progressed so other factors could be affected their 
process. These can be listed as a. Patient and sample characteristics prior the analysis b. 
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Laboratory bench work and growth of the cells during the analysis c. Optimization of the fine 
techniques of analysis as RNA extraction, Nanodrop purity analysis and finally qRT-PCR 
process. In all these 3 points as mentioned before in the paragraph it was a period of training 
and familiarization of the techniques and change of the philosophy of been a researcher and 
not a cardiac surgeon!  
Secondarily and together with the same idea of the previous limitation it is evident in this 
thesis that only one sample of the RV reached a full analysis.  A number of 5 samples that 
have been analyzed from RV chamber after being harvested from human myocardium have 
not been grown in culture despite using the same techniques for more than 2 weeks. This can 
be a limitation but even a finding on its own as the RV is probably hosting  less numbers of 
eCSCs due to her low pressure system with less chances of require regeneration so niches of 
eCSCs are locating  in chambers with high turnover  and chance of myocardial injury like 
LV. On the other hand as the RA and the LA  appendices have embryological  remnants of 
cell progenitors so  the heart keeps niches of eCSCs for further need in case of myocardial 
injury. The unique sample that has been successfully shown isolated eCSCs cells and 
completed all the analysis of the RV was from the endocardial layer of the RV near to the 
tricuspid valve and not the epicardial layer. This was a surgeon’s choice in order to eliminate 
the risks of bleeding during harvesting and avoid patient mortality and morbidity. The 
participating surgeon had been asked to give a minimum of a 2-3 cm size sample from the 
cardiac chamber location; however this was on his discretion after taking in consideration the 
size of the heart and the complexity of the operation. Thus the size of the harvested sample 
was a limiting factor of the amount of cells that can be isolated. The RV sample was lower in 
weight, but still sufficient to give a number of cells after isolation. All the other RV samples 
which were used have been small and muscular but after the enzymatic isolation and cell 
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culture no cells were identified and probably were lost during the various procedures of the 
isolation.  
Thirdly the size of the samples was not the only limiting factor of the number of cells that 
been isolated as small samples showed a good amount of eCSCs and bigger samples showed 
fewer eCSCs. Samples like the RA1 which weighed ~ 1 gram, at the end of the isolation and 
MACS procedure yielded a minimal number of cells and lower than those published in our 
previous studies of our group by Torella (106) who suggested a number of about 45,000 
eCSCs   per gram of tissue; specifically of this sample RA1 the sample harvested was a RA 
appendix which was having not only muscular layers but a significant layer of epicardial fat 
which was involving most of the area of the RA appendix. So the ideal weight has not been 
precisely calculated after eliminating the fat tissues or other fibrous tissues even after 
meticulous and precise sample mincing prior to enzymatic isolation. Due to this limitation 
despite the careful and meticulous enzymatic isolation and cell culture, the cells from some 
samples were still less from the cells reported in the literature. For this reason a small sample 
with fewer cells after MACS procedure when platted and put on in cell culture grow well in a 
period of 2-3 weeks in culture with CSCs growth medium. Probably for future work when we 
redesign of the protocol of harvesting  the samples, instead of  taking in consideration the real 
weight, it will be more accurate  the ideal weight  of the sample and  correlate with the 
number of cells presented during the enzymatic isolation and MACS procedure. 
Lastly using the qRT-PCR we tried to give a better and real time analysis of the expression of 
the genes from the primary and secondary heart field. As mentioned earlier in the discussion 
some of the genes had minimal or negligible expression. This can be explained with poor 
design of primers however for the FGF genes that showed poor expression and abnormal 
melting curves there were only 3 isoforms for humans and only the best of these have been 
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used in order to achieve results. It could be argued that redesign again and redo the same 
analysis could show different results or even confirm these results.  
7. CONCLUSIONS 
Based on our data it would appear that isolated eCSCs are indistinguishable and 
interchangeable throughout the myocardium. These c-kitpos CD45neg e-CSCs are distributed 
throughout the myocardium in all 4 chambers of the human heart. They don’t appear to have 
a chamber-specific transcript footprint, and are therefore interchangeable between cardiac 
chambers. When isolated from all the 4 human cardiac chambers, they appear to have a 
universal genetic profile despite their chamber of origin; with expression of most of the 
transcripts from the secondary heart field and neglibile express from the PHF.  Their source 
for cell therapy becomes simpler and the atrial appendix which is the most approachable and 
safe structure to harvest becomes the source of choice. Having this information, optimal 
myocardial regeneration strategies either through direct cell transplantation or in situ 
activation of these eCSCs post myocardial infarction or other myocardial insult could be 
applied to treat cardiac failure and regenerate the damaged myocardium with not having the 
risk of regional arrhythmias or change of the function of the cardiac chambers. So we can 
safely conclude that the myocardium harbours generic and not chamber specific eCSCs, and 
this it will determine future cell replacement therapy in patients. 
8. FUTURE DIRECTIONS 
With the results and new findings of this thesis we tried to prove the hypothesis that the 
human myocardium harbours eCSCs which are universal and can be potentially 
interchangeable between cardiac chambers. In order to explore more this hypothesis the next 
step of this project has a specific aim which is describing on the next paragraph and it will be 
taking place in the next year in our laboratory. The following step will have the objective to 
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use these cells in an in vivo model and then in clinical practice in order to cure ischemic heart 
disease and chronic heart failure.  
The next steps specific aim is taking in consideration the same idea where we will try to 
characterize and compare the growth, multi-potential and differentiation properties of human 
eCSCs isolated from each of the four chambers of the heart. Pieces of myocardium will be 
obtained as before from all 4 chambers of the adult human heart of patients (male, >18 years, 
n=10 for each cardiac chamber) undergoing cardiac surgery or transplant surgery. Ethical 
approval for these procedures will be given by NREC (08/H1306/91). Cardiac cells will be 
isolated using enzymatic dissociation of the human myocardial tissue. eCSCs will be isolated 
from the mixed population of small cardiac cells by immune-sorting for CD45 negative and 
then c-kit using magnetic microbeads (Miltenyi)® . The degree of enrichment of the sorted 
cells obtained by magnetic activated cell sorting will be determined by FACS and Cytospin 
immunocytochemistry. An aliquot of c-kitpos eCSCs will be characterised for expression of 
genes for ‘stemness’ i.e. Oct3/4, Bmi-1, Rex1, TERT, by quantitative RT-PCR (qRT-PCR) 
and other stem cell markers, i.e. CD133, Flk1 by FACS. 
The rest of the eCSCs will be plated on gelatin-coated dishes in DMEM/F12 (Gibco®) media 
supplemented with 10% serum, 10ng/ml bFGF and 10 ng/ml LIF (Growth Medium). To 
optimize the expansion of eCSCs we will define a media conditioned with small molecules 
(e.g. a cocktail of TGF-b inhibitor, PDK-1 activator, and ERK1/2 inhibitor) without the need 
for adding animal serum. Then we will assess and compare the growth, multi-potency and 
differentiation potential of eCSCs from different cardiac chambers using in vitro assays of 
clonogenicity, cardiosphere formation, self-renewal, cell proliferation and multipotency. For 
clonogenicity, eCSCs will be serially diluted and deposited into one cell/well in 96-well 
plates, for the generation of single-cell clones. The clonal efficiency of eCSCs isolated from 
each chamber will be assessed for 10 x 96 well plates and expressed as a percentage. For cell 
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proliferation, eCSCs and clones will be measured over 24 hours using the BrdU incorporation 
assay (Roche®). For self-renewal, eCSCs will be grown past the population doubling limit of 
somatic cells (>40), and sub-cloned at every 10th passage and assessed for maintenance of 
clonogenicity and primitive stemness genes by qRT-PCR. For cardiosphere formation, eCSC 
clones will be grown and expanded and then placed into bacterial coated dishes with 
cardiosphere-generation media (DMEM/Hams F12, 10ng/ml LIF, Insulin-Transferrin-
Selenium, B27 and N2 supplements).  
The number of cardiospheres generated will be assessed and the ability of eCSCs from each 
chamber to generate primary, secondary and tertiary cardiospheres evaluated. To determine 
eCSC multi-potency, the progeny of a single clone generated cardiosphere expresses 
biochemical markers of cardiomyocytes (Nkx2.5, GATA-4, MEF2C, α-sarcomeric actin, α-
cardiac actinin, troponin I, troponin T, cardiac myosin heavy chain, connexin 43), smooth 
muscle (GATA-6, α-smooth muscle actin) and endothelial (Ets1, CD31, von Willebrand 
factor) cells. The stained cells will be analysed and counted by confocal microscopy (Zeiss 
LSM-510). eCSCs myogenic differentiation potential will be assessed utilising a unique 
cardiosphere myogenic beating assay. The type of cardiac muscle cells produced from eCSCs 
from each chamber will be assessed for their mechanical and electrical properties. Also, they 
will be assessed for the expression of chamber-specific atrial and ventricular myosin light 
chain (MLC) by immune-staining and qRT-PCR (i.e. MLC-2a, which is atrial specific, and 
MLC2v, which is the ventricular specific. In a further step small animal myocardial infarction 
regeneration assay in vivo will determine the regenerative potential of the c-kitpos eCSCs 
isolated form the atria and ventricles using animal myocardial infarction regeneration assay in 
vivo in the nude rat heart. 
In this stage in the in vivo model we will determine whether the pattern of gene and protein  
expression (by qRT-PCR, immunocytochemistry cardiosphere myogenic beating assay in 
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vitro and calcium transients) of new cardiomyocytes derived from the eCSCs both in vitro 
and in vivo recapitulates ontogeny or is common for all the eCSCs irrespective of the 
chamber of origin.  
These studies have a fundamental importance on designing protocols for myocardial 
regeneration, and it will make these protocols standardized for the treatment of myocardial 
infarction and chronic heart failure. In the short term it will be expected that the results of 
these studies will be used to devise a protocol to undertake a clinical trial utilising eCSCs for 
myocardial regenerative therapy. This could have a major impact on the future treatment of 
ischemic heart disease and chronic heart failure. 
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